<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?>
<?SourceDTD.Version 1.0?>
<?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Environ Health Perspect</journal-id>
    <journal-id journal-id-type="iso-abbrev">Environ. Health Perspect</journal-id>
    <journal-id journal-id-type="publisher-id">EHP</journal-id>
    <journal-title-group>
      <journal-title>Environmental Health Perspectives</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0091-6765</issn>
    <issn pub-type="epub">1552-9924</issn>
    <publisher>
      <publisher-name>Environmental Health Perspectives</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6792352</article-id>
    <article-id pub-id-type="publisher-id">EHP5314</article-id>
    <article-id pub-id-type="doi">10.1289/EHP5314</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Paul-Friedman</surname>
          <given-names>Katie</given-names>
        </name>
        <xref ref-type="aff" rid="a1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Martin</surname>
          <given-names>Matt</given-names>
        </name>
        <xref ref-type="aff" rid="a1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Crofton</surname>
          <given-names>Kevin M.</given-names>
        </name>
        <xref ref-type="aff" rid="a1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hsu</surname>
          <given-names>Chia-Wen</given-names>
        </name>
        <xref ref-type="aff" rid="a2">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sakamuru</surname>
          <given-names>Srilatha</given-names>
        </name>
        <xref ref-type="aff" rid="a3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhao</surname>
          <given-names>Jinghua</given-names>
        </name>
        <xref ref-type="aff" rid="a3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xia</surname>
          <given-names>Menghang</given-names>
        </name>
        <xref ref-type="aff" rid="a3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huang</surname>
          <given-names>Ruili</given-names>
        </name>
        <xref ref-type="aff" rid="a3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Stavreva</surname>
          <given-names>Diana A.</given-names>
        </name>
        <xref ref-type="aff" rid="a4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Soni</surname>
          <given-names>Vikas</given-names>
        </name>
        <xref ref-type="aff" rid="a4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Varticovski</surname>
          <given-names>Lyuba</given-names>
        </name>
        <xref ref-type="aff" rid="a4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Raziuddin</surname>
          <given-names>Razi</given-names>
        </name>
        <xref ref-type="aff" rid="a4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hager</surname>
          <given-names>Gordon L.</given-names>
        </name>
        <xref ref-type="aff" rid="a4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Houck</surname>
          <given-names>Keith A.</given-names>
        </name>
        <xref ref-type="aff" rid="a1">
          <sup>1</sup>
        </xref>
      </contrib>
      <aff id="a1"><label>1</label>National Center for Computational Toxicology, Office of Research and Development, <institution>U.S. Environmental Protection Agency</institution>, Research Triangle Park, North Carolina, <country>USA</country></aff>
      <aff id="a2"><label>2</label>Center for Drug Evaluation and Research, <institution>U.S. Food and Drug Administration</institution>, Washington, DC, <country>USA</country></aff>
      <aff id="a3"><label>3</label>National Center for Advancing Translational Sciences, <institution>National Institutes of Health (NIH)</institution>, Bethesda, Maryland, <country>USA</country></aff>
      <aff id="a4"><label>4</label>Center for Cancer Research, National Cancer Institute, <institution>NIH</institution>, Bethesda, Maryland, <country>USA</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Address correspondence to Keith Houck, Ph.D, U.S. EPA, 109 T.W. Alexander Dr., D143-02, Research Triangle Park, NC 27709 USA. Telephone: (919) 541-5519. Email: <email>Houck.keith@epa.gov</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>30</day>
      <month>9</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>9</month>
      <year>2019</year>
    </pub-date>
    <volume>127</volume>
    <issue>9</issue>
    <elocation-id>097009</elocation-id>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>3</month>
        <year>2019</year>
      </date>
      <date date-type="rev-recd">
        <day>28</day>
        <month>8</month>
        <year>2019</year>
      </date>
      <date date-type="accepted">
        <day>31</day>
        <month>8</month>
        <year>2019</year>
      </date>
    </history>
    <permissions>
      <license license-type="open-access">
        <license-p><italic>EHP</italic> is an open-access journal published with support from the National Institute of Environmental Health Sciences, National Institutes of Health. All content is public domain unless otherwise noted.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="ehp-127-097009.pdf"/>
    <abstract>
      <sec>
        <title>Background:</title>
        <p>Thyroid hormone receptors (TRs) are critical endocrine receptors that regulate a multitude of processes in adult and developing organisms, and thyroid hormone disruption is of high concern for neurodevelopmental and reproductive toxicities in particular. To date, only a small number of chemical classes have been identified as possible TR modulators, and the receptors appear highly selective with respect to the ligand structural diversity. Thus, the question of whether TRs are an important screening target for protection of human and wildlife health remains.</p>
      </sec>
      <sec>
        <title>Objective:</title>
        <p>Our goal was to evaluate the hypothesis that there is limited structural diversity among environmentally relevant chemicals capable of modulating TR activity via the collaborative interagency Tox21 project.</p>
      </sec>
      <sec>
        <title>Methods:</title>
        <p>We screened the Tox21 chemical library (8,305 unique structures) in a quantitative high-throughput, cell-based reporter gene assay for TR agonist or antagonist activity. Active compounds were further characterized using additional orthogonal assays, including mammalian one-hybrid assays, coactivator recruitment assays, and a high-throughput, fluorescent imaging, nuclear receptor translocation assay.</p>
      </sec>
      <sec>
        <title>Results:</title>
        <p>Known agonist reference chemicals were readily identified in the TR transactivation assay, but only a single novel, direct agonist was found, the pharmaceutical betamipron. Indirect activation of TR through activation of its heterodimer partner, the retinoid-X-receptor (RXR), was also readily detected by confirmation in an RXR agonist assay. Identifying antagonists with high confidence was a challenge with the presence of significant confounding cytotoxicity and other, non-TR-specific mechanisms common to the transactivation assays. Only three pharmaceuticals—mefenamic acid, diclazuril, and risarestat—were confirmed as antagonists.</p>
      </sec>
      <sec>
        <title>Discussion:</title>
        <p>The results support limited structural diversity for direct ligand effects on TR and imply that other potential target sites in the thyroid hormone axis should be a greater priority for bioactivity screening for thyroid axis disruptors. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1289/EHP5314">https://doi.org/10.1289/EHP5314</ext-link></p>
      </sec>
    </abstract>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>Introduction</title>
    <p>Thyroid hormones are present in numerous tissues, including brain, pituitary, heart, fat, liver, and bone and regulate many processes, from metabolic and cardiac output rate to neurodevelopment (<xref rid="c14" ref-type="bibr">Cioffi et al. 2018</xref>; <xref rid="c21" ref-type="bibr">Duncan Bassett and Williams 2018</xref>; <xref rid="c28" ref-type="bibr">Gilbert et al. 2012</xref>; <xref rid="c68" ref-type="bibr">Oetting and Yen 2007</xref>; <xref rid="c93" ref-type="bibr">Williams 2008</xref>; <xref rid="c94" ref-type="bibr">Yen 2001</xref>; <xref rid="c98" ref-type="bibr">Zoeller et al. 2007</xref>). Thyroid hormones, specifically triiodothyronine (T3), predominantly exert their genomic action via interaction with thyroid hormone receptor (TRs), a family of nuclear receptor transcriptional factors including TR<inline-formula><mml:math id="m1"><mml:mrow><mml:mi mathvariant="normal">α</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="m2"><mml:mrow><mml:mi mathvariant="normal">β</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="m3"><mml:mrow><mml:mi mathvariant="normal">β</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="m4"><mml:mrow><mml:mi mathvariant="normal">β</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>, expressed in a specific pattern during development and adulthood, based on their regulatory function (<xref rid="c11" ref-type="bibr">Cheng et al. 2010</xref>; <xref rid="c83" ref-type="bibr">Tancevski et al. 2011</xref>). The gene targets of the transcriptional action of TRs continue to be elucidated, including reports of genes in the brain, heart, and liver (<xref rid="c30" ref-type="bibr">Grijota-Martínez et al. 2011</xref>; <xref rid="c11" ref-type="bibr">Cheng et al. 2010</xref>; <xref rid="c29" ref-type="bibr">Govindan et al. 2009</xref>; <xref rid="c55" ref-type="bibr">Lonard et al. 2007</xref>) that demonstrate the broad physiological relevance of TR signaling at all life stages. <inline-formula><mml:math id="m5"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> is present in many tissues but is most highly expressed in liver, whereas <inline-formula><mml:math id="m6"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> is highly expressed in the anterior pituitary (<xref rid="c94" ref-type="bibr">Yen 2001</xref>) and is thought to be a primary determinant of hypothalamic–pituitary–thyroid axis regulation (<xref rid="c93" ref-type="bibr">Williams 2008</xref>). <inline-formula><mml:math id="m7"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> is highly expressed in neurons (<xref rid="c87" ref-type="bibr">Wallis et al. 2010</xref>; <xref rid="c94" ref-type="bibr">Yen 2001</xref>) during fetal development, with decreased expression in the weeks following birth to coincide with dramatic increases in <inline-formula><mml:math id="m8"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, suggesting that a developmental pattern of TR isoforms expression is related to receptor-specific regulation of genes for neurodevelopment (<xref rid="c94" ref-type="bibr">Yen 2001</xref>). Thus, interest in screening for xenobiotics that may modulate TR is underscored by the breadth of physiology controlled by these receptors.</p>
    <p>TRs demonstrated a stringent, selective binding profile in medicinal chemistry and X-ray crystallographic receptor studies, suggesting that only chemicals with high homology to thyroid hormones will act at this regulatory node (<xref rid="c75" ref-type="bibr">Ribeiro et al. 1998</xref>; <xref rid="c86" ref-type="bibr">Wagner et al. 1995</xref>). TRs form homodimers and heterodimers with other nuclear receptors, in particular the retinoid-X receptor (RXR), forming a regulatory complex (<xref rid="c1" ref-type="bibr">Araki et al. 2005</xref>; <xref rid="c8" ref-type="bibr">Burris et al. 2013</xref>), and recruit co-activators and co-repressors in order to interact with transcriptional response elements upstream of TR-regulated genes (<xref rid="c11" ref-type="bibr">Cheng et al. 2010</xref>; <xref rid="c29" ref-type="bibr">Govindan et al. 2009</xref>; <xref rid="c52" ref-type="bibr">Lee and Yen 1999</xref>). TR modulators have been developed as potential therapeutics, including the <inline-formula><mml:math id="m9"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> isoform-selective synthetic agonists GC-1 and KB2115 (<xref rid="c4" ref-type="bibr">Berkenstam et al. 2008</xref>; <xref rid="c12" ref-type="bibr">Chiellini et al. 1998</xref>) and NH-3 as a <inline-formula><mml:math id="m10"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> antagonist (<xref rid="c13" ref-type="bibr">Chiellini et al. 2002</xref>; <xref rid="c54" ref-type="bibr">Lim et al. 2002</xref>) but are limited in number and structural diversity.</p>
    <p><italic>In vitro</italic> assays are available to demonstrate that some nonpharmaceutical, environmental chemicals can interact with TRs and support more extensive evaluation of such compounds (<xref rid="c18" ref-type="bibr">DeVito et al. 1999</xref>; <xref rid="c65" ref-type="bibr">Murk et al. 2013</xref>; <xref rid="c96" ref-type="bibr">Zoeller 2005</xref>). The <italic>in vitro</italic> approaches used included several nuclear TR transactivation assays: cell lines with endogenous TRs and stable luciferase reporter genes regulated by TR-responsive promoters; stable reporter gene assays in cell lines expressing specific, recombinant TR isoforms; cell lines co-transfected with a specific GAL4-TR expression vector and a corresponding upstream activation sequence (UAS); transiently transfected versions of these assays; and stable reporter assays in yeast (<xref rid="c65" ref-type="bibr">Murk et al. 2013</xref>). Examples of modulators identified in receptor-reporter assays include hydroxylated polychlorinated biphenyls (OH-PCBs) and hydroxylated polybrominated diphenyl ethers (OH-BDEs) as TR agonists and amiodarone and sodium arsenite as antagonists (<xref rid="c24" ref-type="bibr">Freitas et al. 2011</xref>; <xref rid="c66" ref-type="bibr">Norman and Lavin 1989</xref>). In addition, there are several conflicting reports on the <italic>in vitro</italic> receptor-mediated activity of bisphenol A (BPA) and its halogenated analogs, including tetrabromobisphenol A and tetrachlorobisphenol A. These chemicals appear to be weak TR antagonists with some potential agonist-like behavior at lower concentrations similar to the effects of selective estrogen receptor modulators on cell proliferation (<xref rid="c24" ref-type="bibr">Freitas et al. 2011</xref>; <xref rid="c44" ref-type="bibr">Kitamura et al. 2002</xref>; <xref rid="c62" ref-type="bibr">Moriyama et al. 2002</xref>; <xref rid="c80" ref-type="bibr">Schriks et al. 2006</xref>). Miyazaki et al. (<xref rid="c61" ref-type="bibr">2008</xref>) and Ibhazehiebo et al. (<xref rid="c38" ref-type="bibr">2011</xref>) explained weak suppression of TR-mediated transcription by nondioxin-like PCBs and polybrominated bisphenols as caused by dissociating TR from the TR response element (TRE) although coregulator recruitment was unaffected. Kollitz et al. (<xref rid="c48" ref-type="bibr">2018</xref>) demonstrated T3-competitive binding of halogenated bisphenols and diphenyl ethers to human and zebrafish <inline-formula><mml:math id="m11"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> but did not examine functional activity. Several classes of substances were identified previously as interacting with TRs in a HepG2 cell transactivation assay for human <inline-formula><mml:math id="m12"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m13"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula>, but with limited efficacy, including a variety of food constituents, that is, genistein, silymarin, and xanthohumol; estrogenic plasticizers including 4-nonylphenol and BPA; ultraviolet-blocking chemicals benzophenone-2 and -3; and the pesticides linuron and procymidone (<xref rid="c33" ref-type="bibr">Hofmann et al. 2009</xref>). Thus, it is important to screen a library that includes environmentally relevant chemicals for potential endocrine-disrupting interactions on TR functional activity and characterize the potential ligands identified to evaluate the hypothesis that the TR is likely not a primary target for xenobiotic disruption of thyroid homeostasis.</p>
    <p>This hypothesis fits within the objectives of the U.S. Environmental Protection Agency (U.S. EPA) Endocrine Disruption Screening Program (EDSP) to screen pesticidal actives and inerts and chemicals present in the environment for their potential to disrupt endocrine function in both humans and wildlife. We utilized the Tox21 consortium (<xref rid="c42" ref-type="bibr">Kavlock et al. 2009</xref>), which employs a large set of high-throughput screening (HTS) assays with the goal of profiling thousands of environmentally relevant chemicals for their potential to perturb biological pathways, including endocrine function. The rat pituitary GH3 TR reporter gene cell line, expressing endogenous <inline-formula><mml:math id="m14"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m15"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula>, was used to screen the Tox21 8,305-chemical library, followed by orthogonal assays that were then used to characterize the potential agonists and antagonists identified. These data provide evidence to evaluate the relative contribution of TR disruption to xenobiotic-induced adverse outcomes for thyroid axis function and to further inform development of predictive tools for thyroid signaling disruption.</p>
  </sec>
  <sec id="s2">
    <title>Methods</title>
    <sec id="s2.1">
      <title>Chemical Library Screened</title>
      <p>The Tox21 chemical library contained 10,496 samples and 8,305 unique structures at the time of this screen. The compound classes include industrial chemicals, sunscreen additives, flame retardants, pesticides and selected metabolites, plasticizers, solvents, food additives, natural product components, drinking-water disinfection by-products, preservatives, therapeutic agents, and chemical synthesis by-products. Identity and purity quality control analysis of the entire library was conducted using a tiered approach beginning with a high-throughput high-performance liquid chromatography system. Results for the library are available at <ext-link ext-link-type="uri" xlink:href="https://tripod.nih.gov/tox21/samples">https://tripod.nih.gov/tox21/samples</ext-link> with results for specific compounds also shown in this manuscript. Note that these techniques are high-throughput analytical methods and should be considered supportive, but not necessarily definitive, data for chemical identification and purity for the tested sample solutions in dimethyl sulfoxide (DMSO).</p>
    </sec>
    <sec id="s2.2">
      <title>TR Screening Assays</title>
      <p>The assays used in this study, including cell line, primary function of the assay in the current work, and its unique assay end point identifier within the U.S. EPA’s invitrodb_v2 database (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.23645/epacomptox.6062623.v1">https://doi.org/10.23645/epacomptox.6062623.v1</ext-link>) are listed in <xref rid="t1" ref-type="table">Table 1</xref> and the project workflow in Figure S1.</p>
      <table-wrap id="t1" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Assay names (aenm) and assay end point identification (aeid) values used in the text and invitrodb database together with mode and purpose of assay.</p>
        </caption>
        <alt-text>Table 1 lists assay short name in the first column; the corresponding invitrodb: Assay Name (aenm), invitrodb: aeid, cell line, assay mode, and function are listed in the other columns.</alt-text>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" id="t1c1" scope="col" rowspan="1" colspan="1">Assay short name</th>
              <th align="center" id="t1c2" scope="col" rowspan="1" colspan="1">invitrodb: aenm</th>
              <th align="center" id="t1c3" scope="col" rowspan="1" colspan="1">invitrodb: aeid</th>
              <th align="center" id="t1c4" scope="col" rowspan="1" colspan="1">Cell line</th>
              <th align="center" id="t1c5" scope="col" rowspan="1" colspan="1">Assay mode</th>
              <th align="center" id="t1c6" scope="col" rowspan="1" colspan="1">Function</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" id="t1c7" scope="row" headers="t1c1" rowspan="1" colspan="1">GH3-TRE-Ag</td>
              <td align="left" headers="t1c2 t1c7" rowspan="1" colspan="1">TOX21_TR_LUC_GH3_Agonist</td>
              <td align="char" char="." headers="t1c3 t1c7" rowspan="1" colspan="1">803</td>
              <td align="left" headers="t1c4 t1c7" rowspan="1" colspan="1">GH3-TRE-Luc</td>
              <td align="left" headers="t1c5 t1c7" rowspan="1" colspan="1">Agonist</td>
              <td align="left" headers="t1c6 t1c7" rowspan="1" colspan="1">Primary qHTS</td>
            </tr>
            <tr>
              <td align="left" id="t1c8" scope="row" headers="t1c1" rowspan="1" colspan="1">GH3-TRE-Antag</td>
              <td align="left" headers="t1c2 t1c8" rowspan="1" colspan="1">TOX21_TR_LUC_GH3_Antagonist</td>
              <td align="char" char="." headers="t1c3 t1c8" rowspan="1" colspan="1">804</td>
              <td align="left" headers="t1c4 t1c8" rowspan="1" colspan="1">GH3-TRE-Luc</td>
              <td align="left" headers="t1c5 t1c8" rowspan="1" colspan="1">Antagonist</td>
              <td align="left" headers="t1c6 t1c8" rowspan="1" colspan="1">Primary qHTS</td>
            </tr>
            <tr>
              <td align="left" id="t1c9" scope="row" headers="t1c1" rowspan="1" colspan="1">GH3-TRE-Via</td>
              <td align="left" headers="t1c2 t1c9" rowspan="1" colspan="1">TOX21_TR_LUC_GH3_Antagonist_viability</td>
              <td align="char" char="." headers="t1c3 t1c9" rowspan="1" colspan="1">805</td>
              <td align="left" headers="t1c4 t1c9" rowspan="1" colspan="1">GH3-TRE-Luc</td>
              <td align="left" headers="t1c5 t1c9" rowspan="1" colspan="1">Viability</td>
              <td align="left" headers="t1c6 t1c9" rowspan="1" colspan="1">Cytotoxicity</td>
            </tr>
            <tr>
              <td align="left" id="t1c10" scope="row" headers="t1c1" rowspan="1" colspan="1">GH3-TRE-Ag-Followup</td>
              <td align="left" headers="t1c2 t1c10" rowspan="1" colspan="1">TOX21_TR_LUC_GH3_Agonist_Followup</td>
              <td align="char" char="." headers="t1c3 t1c10" rowspan="1" colspan="1">2226</td>
              <td align="left" headers="t1c4 t1c10" rowspan="1" colspan="1">GH3-TRE-Luc</td>
              <td align="left" headers="t1c5 t1c10" rowspan="1" colspan="1">Agonist</td>
              <td align="left" headers="t1c6 t1c10" rowspan="1" colspan="1">Confirmation</td>
            </tr>
            <tr>
              <td align="left" id="t1c11" scope="row" headers="t1c1" rowspan="1" colspan="1">GH3-TRE-Antag-Followup</td>
              <td align="left" headers="t1c2 t1c11" rowspan="1" colspan="1">TOX21_TR_LUC_GH3_Antagonist_Followup</td>
              <td align="char" char="." headers="t1c3 t1c11" rowspan="1" colspan="1">2227</td>
              <td align="left" headers="t1c4 t1c11" rowspan="1" colspan="1">GH3-TRE-Luc</td>
              <td align="left" headers="t1c5 t1c11" rowspan="1" colspan="1">Antagonist</td>
              <td align="left" headers="t1c6 t1c11" rowspan="1" colspan="1">Confirmation</td>
            </tr>
            <tr>
              <td align="left" id="t1c12" scope="row" headers="t1c1" rowspan="1" colspan="1">TRb-bla</td>
              <td align="left" headers="t1c2 t1c12" rowspan="1" colspan="1">TOX21_TRB_BLA_Antagonist_Followup_ratio</td>
              <td align="char" char="." headers="t1c3 t1c12" rowspan="1" colspan="1">2240</td>
              <td align="left" headers="t1c4 t1c12" rowspan="1" colspan="1"><inline-formula><mml:math id="m16"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T</td>
              <td align="left" headers="t1c5 t1c12" rowspan="1" colspan="1">Antagonist</td>
              <td align="left" headers="t1c6 t1c12" rowspan="1" colspan="1">Specificity</td>
            </tr>
            <tr>
              <td align="left" id="t1c13" scope="row" headers="t1c1" rowspan="1" colspan="1">RXRa-bla-Ag</td>
              <td align="left" headers="t1c2 t1c13" rowspan="1" colspan="1">TOX21_TR_RXR_BLA_Agonist_Followup_ratio</td>
              <td align="char" char="." headers="t1c3 t1c13" rowspan="1" colspan="1">2253</td>
              <td align="left" headers="t1c4 t1c13" rowspan="1" colspan="1"><inline-formula><mml:math id="m17"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T</td>
              <td align="left" headers="t1c5 t1c13" rowspan="1" colspan="1">Agonist</td>
              <td align="left" headers="t1c6 t1c13" rowspan="1" colspan="1">Specificity</td>
            </tr>
            <tr>
              <td align="left" id="t1c14" scope="row" headers="t1c1" rowspan="1" colspan="1">RXRa-bla-Antag</td>
              <td align="left" headers="t1c2 t1c14" rowspan="1" colspan="1">TOX21_TR_RXR_BLA_Antagonist_Followup_ratio</td>
              <td align="char" char="." headers="t1c3 t1c14" rowspan="1" colspan="1">2257</td>
              <td align="left" headers="t1c4 t1c14" rowspan="1" colspan="1"><inline-formula><mml:math id="m18"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T</td>
              <td align="left" headers="t1c5 t1c14" rowspan="1" colspan="1">Antagonist</td>
              <td align="left" headers="t1c6 t1c14" rowspan="1" colspan="1">Specificity</td>
            </tr>
            <tr>
              <td align="left" id="t1c15" scope="row" headers="t1c1" rowspan="1" colspan="1">RXRa-Via</td>
              <td align="left" headers="t1c2 t1c15" rowspan="1" colspan="1">TOX21_TR_RXR_BLA_Antagonist_Followup_viability</td>
              <td align="char" char="." headers="t1c3 t1c15" rowspan="1" colspan="1">2258</td>
              <td align="left" headers="t1c4 t1c15" rowspan="1" colspan="1"><inline-formula><mml:math id="m19"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T</td>
              <td align="left" headers="t1c5 t1c15" rowspan="1" colspan="1">Viability</td>
              <td align="left" headers="t1c6 t1c15" rowspan="1" colspan="1">Cytotoxicity</td>
            </tr>
            <tr>
              <td align="left" id="t1c16" scope="row" headers="t1c1" rowspan="1" colspan="1">TRa-coa</td>
              <td align="left" headers="t1c2 t1c16" rowspan="1" colspan="1">TOX21_TRA_COA_Agonist_Followup_ratio</td>
              <td align="char" char="." headers="t1c3 t1c16" rowspan="1" colspan="1">2230</td>
              <td align="left" headers="t1c4 t1c16" rowspan="1" colspan="1">NA</td>
              <td align="left" headers="t1c5 t1c16" rowspan="1" colspan="1">Agonist</td>
              <td align="left" headers="t1c6 t1c16" rowspan="1" colspan="1">Orthogonal</td>
            </tr>
            <tr>
              <td align="left" id="t1c17" scope="row" headers="t1c1" rowspan="1" colspan="1">TRb-coa</td>
              <td align="left" headers="t1c2 t1c17" rowspan="1" colspan="1">TOX21_TRB_BLA_Agonist_Followup_ratio</td>
              <td align="char" char="." headers="t1c3 t1c17" rowspan="1" colspan="1">2236</td>
              <td align="left" headers="t1c4 t1c17" rowspan="1" colspan="1">NA</td>
              <td align="left" headers="t1c5 t1c17" rowspan="1" colspan="1">Agonist</td>
              <td align="left" headers="t1c6 t1c17" rowspan="1" colspan="1">Orthogonal</td>
            </tr>
            <tr>
              <td align="left" id="t1c18" scope="row" headers="t1c1" rowspan="1" colspan="1">GFP-GR-TRb</td>
              <td align="left" headers="t1c2 t1c18" rowspan="1" colspan="1">NA</td>
              <td align="center" headers="t1c3 t1c18" rowspan="1" colspan="1">NA</td>
              <td align="left" headers="t1c4 t1c18" rowspan="1" colspan="1"><inline-formula><mml:math id="m20"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> MCF7</td>
              <td align="left" headers="t1c5 t1c18" rowspan="1" colspan="1">Agonist and antagonist</td>
              <td align="left" headers="t1c6 t1c18" rowspan="1" colspan="1">Orthogonal</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TF1">
            <p>Note: Ag, agonist; Antag, antagonist; bla, beta-lactamase; coa, coactivator; GFP, green fluorescent protein;GH3, rat pituitary cell line; GR, glucocorticoid receptor; HEK 293T, human embryonic kidney cell line; LUC, luciferase; MCF7, human breast cancer cell line; NA, not applicable; qHTS, quantitative high-throughput screen; RXRa, retinoid X receptor alpha; TRa, thyroid hormone receptor alpha; TRb, thyroid hormone receptor beta; TRE, thyroid hormone receptor response element; UAS, upstream activating sequence; Via, viability.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p><bold><italic>GH3-TRE screening assays.</italic> Cell line and culture.</bold> The development of the GH3-TRE-Luc cell line for assays used in the primary screening was previously described (<xref rid="c24" ref-type="bibr">Freitas et al. 2011</xref>, <xref rid="c25" ref-type="bibr">2014</xref>). Briefly, a thyroid hormone receptor-regulated luciferase reporter containing two thyroid hormone DR4 response elements upstream of an SV40 minimal promoter driving expression of a modified firefly luciferase reporter was stably cloned into the rat pituitary tumor cell line, GH3. The GH3-TRE-Luc cell line was cultured in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) supplemented with 10% fetal bovine serum (FBS; Hyclone, SH30071.03) and <inline-formula><mml:math id="m21"><mml:mrow><mml:mn>100</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">U</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">mL</mml:mi></mml:mrow></mml:math></inline-formula>
<inline-formula><mml:math id="m22"><mml:mrow><mml:mtext>penicillin-</mml:mtext><mml:mn>100</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">mL</mml:mi></mml:mrow></mml:math></inline-formula> streptomycin (Life Technologies).</p>
      <p><bold>Primary screen.</bold> For the primary quantitative high-throughput screen (qHTS) assays, the growth medium from the GH3-TRE-Luc cell culturing flask was replaced with assay medium [DMEM/F-12 medium supplemented with <inline-formula><mml:math id="m23"><mml:mrow><mml:mn>10</mml:mn><mml:mtext>  ng</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">mL</mml:mi></mml:mrow></mml:math></inline-formula> sodium selenite, <inline-formula><mml:math id="m24"><mml:mrow><mml:mn>10</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">mL</mml:mi></mml:mrow></mml:math></inline-formula> human apo-transferrin, <inline-formula><mml:math id="m25"><mml:mrow><mml:mn>10</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula> ethanolamine, <inline-formula><mml:math id="m26"><mml:mrow><mml:mn>10</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">mL</mml:mi></mml:mrow></mml:math></inline-formula> insulin, and <inline-formula><mml:math id="m27"><mml:mrow><mml:mn>500</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">mL</mml:mi></mml:mrow></mml:math></inline-formula> bovine serum albumin (BSA)] overnight prior to the assay. The next day, cells were seeded at 1,500/well in <inline-formula><mml:math id="m28"><mml:mrow><mml:mn>5</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> (agonist mode) and <inline-formula><mml:math id="m29"><mml:mrow><mml:mn>4</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> (antagonist mode) of the assay medium in 1,536-well white/solid plates (Greiner Bio-One North America) using a Multidrop Combi (Thermo Fisher Scientific) dispenser. Chemical samples were serially diluted in DMSO, yielding 15 concentrations for testing. After 5-h incubation at 37°C/5% carbon dioxide (<inline-formula><mml:math id="m30"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">CO</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>) for cell attachment, <inline-formula><mml:math id="m31"><mml:mrow><mml:mn>23</mml:mn><mml:mtext>  nL</mml:mtext></mml:mrow></mml:math></inline-formula> of serially diluted compounds (yielding <inline-formula><mml:math id="m32"><mml:mrow><mml:mn>92</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula> to <inline-formula><mml:math id="m33"><mml:mrow><mml:mn>5</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> final assay concentration) and positive control (T3; agonist format), DMSO only (antagonist format) were transferred to the assay plates using a Pintool station (Wako). To screen compounds that antagonize T3-induced transactivation of TR, an extra <inline-formula><mml:math id="m34"><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> of T3 was added using a BioRAPTER Flying Reagent Dispenser™ (FRD™; Aurora Discovery) on the top of the cell/compound mixtures to achieve a final agonist concentration of <inline-formula><mml:math id="m35"><mml:mrow><mml:mn>1.0</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula>. The assay plates were incubated at 37°C/5% <inline-formula><mml:math id="m36"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">CO</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> for 24 h. For the antagonist mode, a cell viability assay was run in parallel by adding <inline-formula><mml:math id="m37"><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mo>/</mml:mo><mml:mtext>well</mml:mtext></mml:mrow></mml:math></inline-formula> CellTiter-Fluor reagent (Promega Corporation) using an FRD™, and after 30-min incubation at 37°C/5% <inline-formula><mml:math id="m38"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">CO</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, the fluorescence intensity was measured using a ViewLux plate reader (PerkinElmer). For the luciferase reporter gene assay, <inline-formula><mml:math id="m39"><mml:mrow><mml:mn>5</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mo>/</mml:mo><mml:mtext>well</mml:mtext></mml:mrow></mml:math></inline-formula> (agonist format) and <inline-formula><mml:math id="m40"><mml:mrow><mml:mn>4</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mo>/</mml:mo><mml:mtext>well</mml:mtext></mml:mrow></mml:math></inline-formula> (antagonist format) ONE-Glo reagent (Promega Corporation) was added using an FRD™, and after 30-min incubation at room temperature, the luminescence intensity was measured using a ViewLux plate reader. Data were expressed as relative fluorescence units (cell viability assay) and relative luminescence units (luciferase reporter assay).</p>
      <p><bold>Confirmatory screen.</bold> Samples were selected based on an active hit call in the primary qHTS assay, agonist or antagonist format, together with the availability of sample from reserved chemical stocks for the Tox21 library for retesting in the GH3-TRE-Luc assay using the same format at the primary screen. Samples were retested in parallel with <inline-formula><mml:math id="m41"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m42"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> assays in the mammalian one-hybrid assays to assess activity against human TR ligand-binding domains.</p>
      <p><bold><italic>Mammalian one-hybrid beta-lactamase screening assays.</italic> Specificity screening for</bold><inline-formula><mml:math id="m43"><mml:mrow><mml:mi mathvariant="bold">T</mml:mi><mml:mi mathvariant="bold">R</mml:mi><mml:mi mathvariant="bold">β</mml:mi><mml:mo mathvariant="bold">.</mml:mo></mml:mrow></mml:math></inline-formula> The GeneBLAzer™ <inline-formula><mml:math id="m44"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T assay kit for human <inline-formula><mml:math id="m45"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> (Thermo Fisher Scientific; catalog no. K1684) was used as a secondary assay for specificity (<inline-formula><mml:math id="m46"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-bla</mml:mtext></mml:mrow></mml:math></inline-formula>). This assay contained the ligand-binding domain (LBD) of the human <inline-formula><mml:math id="m47"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer™ UAS-bla HEK 293T cell line. The reporter gene, <inline-formula><mml:math id="m48"><mml:mrow><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-lactamase</mml:mtext></mml:mrow></mml:math></inline-formula>, is under the transcriptional control of a UAS that binds the GAL4 DNA-binding domain. A cell viability assay was run in parallel for these cells as well using the CellTiter-Glo viability assay kit.</p>
      <p><inline-formula><mml:math id="m49"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-bla</mml:mtext></mml:mrow></mml:math></inline-formula> cells were dispensed at 3,000 cells/well in <inline-formula><mml:math id="m50"><mml:mrow><mml:mn>5</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> of the assay medium containing phenol red–free DMEM with 2% charcoal-stripped FBS in 1,536-well black-wall/clear-bottom plates using an FRD™. After 5-h incubation at 37°C/5% <inline-formula><mml:math id="m51"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">CO</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> for cell attachment to the well bottom, <inline-formula><mml:math id="m52"><mml:mrow><mml:mn>23</mml:mn><mml:mtext>  nL</mml:mtext></mml:mrow></mml:math></inline-formula> of follow-up compounds dissolved in DMSO, 11 concentrations in triplicate, and the positive control (T3; agonist format) were transferred to the assay plates using a Pintool station. The assay plates were incubated at 37°C/5% <inline-formula><mml:math id="m53"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">CO</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> for 18 h. One microliter LiveBLAzer™ FRET-B/G CCF4-AM substrate was added to each well using an FRD™. After 2-h incubation at room temperature, the fluorescence intensity was measured using an Envision plate reader. Data were expressed as the ratio of <inline-formula><mml:math id="m54"><mml:mrow><mml:mn>460:530</mml:mn><mml:mtext>  nm</mml:mtext></mml:mrow></mml:math></inline-formula>. The cytotoxicity of the compounds was measured in the same plates by adding <inline-formula><mml:math id="m55"><mml:mrow><mml:mn>4</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> of CellTiter-Glo reagent to each well and incubating the plates at room temperature for 30 min. The luminescence intensity was measured using a ViewLux plate reader.</p>
      <p><bold>Specificity screening for RXR.</bold> To assess whether activity at the RXR portion of the TR:RXR heterodimer may have contributed to the GH3-TRE-Luc signal, a GeneBLAzer™ <inline-formula><mml:math id="m56"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T assay (<inline-formula><mml:math id="m57"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-bla</mml:mtext></mml:mrow></mml:math></inline-formula>) was also run (Thermo Fisher Scientific; catalog no. K1697). <inline-formula><mml:math id="m58"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-bla</mml:mtext></mml:mrow></mml:math></inline-formula> cells were seeded at 2,500/well in <inline-formula><mml:math id="m59"><mml:mrow><mml:mn>6</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> of the assay medium containing phenol red–free DMEM with 2% charcoal-stripped FBS in 1,536-well black-wall/clear-bottom plates (Greiner Bio-One North America) using a Multidrop Combi dispenser. After 5-h incubation at 37°C/5% <inline-formula><mml:math id="m60"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">CO</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> for cell attachment, <inline-formula><mml:math id="m61"><mml:mrow><mml:mn>23</mml:mn><mml:mtext>  nL</mml:mtext></mml:mrow></mml:math></inline-formula> of follow-up compounds dissolved in DMSO, 11 concentrations in triplicate, and the positive control (9-<italic>cis</italic> retinoic acid) were transferred to the assay plates using a Pintool station. The assay plates were incubated at 37°C/5% <inline-formula><mml:math id="m62"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">CO</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> for 16 h. One microliter of LiveBLAzer™ FRET-B/G CCF4-AM substrate (Life Technologies) was added to each well using an FRD™. After 2-h incubation at room temperature, the fluorescence intensity was measured using an Envision plate reader (PerkinElmer). Data were expressed as the ratio of <inline-formula><mml:math id="m63"><mml:mrow><mml:mn>460:530</mml:mn><mml:mtext>  nm</mml:mtext></mml:mrow></mml:math></inline-formula>.</p>
      <p><bold><italic>Orthogonal assays.</italic> Coactivator recruitment assays (TRa-coa and TRb-coa).</bold> The LanthaScreen™ TR-FRET <inline-formula><mml:math id="m64"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m65"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> coactivator assay kits were used to determine TR activity in a cell-free functional assay in a 1,536-well qHTS format. Briefly, <inline-formula><mml:math id="m66"><mml:mrow><mml:mn>4</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> mixture of the receptor LBDs expressed as glutathione <italic>S</italic>-transferase (GST) fusion proteins (<inline-formula><mml:math id="m67"><mml:mrow><mml:mn>2.5</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> for <inline-formula><mml:math id="m68"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m69"><mml:mrow><mml:mn>5.0</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> for <inline-formula><mml:math id="m70"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula>) and BSA (0.10%; Sigma-Aldrich) were incubated with <inline-formula><mml:math id="m71"><mml:mrow><mml:mn>23</mml:mn><mml:mtext>  nL</mml:mtext></mml:mrow></mml:math></inline-formula> of control or test compound. A time-resolved fluorescence resonance energy transfer (TR-FRET) signal was indicative of coactivator recruitment using a <inline-formula><mml:math id="m72"><mml:mrow><mml:mn>2</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:math></inline-formula> mixture of fluorescein-labeled SRC-2 peptide (<inline-formula><mml:math id="m73"><mml:mrow><mml:mn>200</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula>) and terbium-labeled anti-GST antibody (<inline-formula><mml:math id="m74"><mml:mrow><mml:mn>2</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula>), which transferred resonance energy to the fluorescein tag on the coactivator peptide following recruitment to the receptor. Fluorescence emission ratios (<inline-formula><mml:math id="m75"><mml:mrow><mml:mn>520:495</mml:mn><mml:mtext>  nm</mml:mtext></mml:mrow></mml:math></inline-formula>) were collected by an Envision plate reader (excitation at <inline-formula><mml:math id="m76"><mml:mrow><mml:mn>340</mml:mn><mml:mtext>  nm</mml:mtext></mml:mrow></mml:math></inline-formula> and emissions at 495 and <inline-formula><mml:math id="m77"><mml:mrow><mml:mn>520</mml:mn><mml:mtext>  nm</mml:mtext></mml:mrow></mml:math></inline-formula>), and the measured values were normalized to 0% activity using DMSO-only wells and 100% activity using T3 control wells.</p>
      <p><bold>Nuclear translocation assay (</bold><inline-formula><mml:math id="m78"><mml:mrow><mml:mi mathvariant="bold">GFP</mml:mi><mml:mtext>-</mml:mtext><mml:mi mathvariant="bold">GR</mml:mi><mml:mtext>-</mml:mtext><mml:mi mathvariant="bold">TR</mml:mi><mml:mi mathvariant="bold">β</mml:mi></mml:mrow></mml:math></inline-formula><bold>).</bold> Ligand-induced cytoplasm-to-nuclear translocation/stabilization of the TR was determined by using a variation of a glucocorticoid receptor (GR) nuclear translocation assay (<xref rid="c36" ref-type="bibr">Htun et al. 1996</xref>; <xref rid="c82" ref-type="bibr">Stavreva et al. 2016</xref>). Briefly, a <inline-formula><mml:math id="m79"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> chimeric receptor was constructed by fusing the human GR N-terminus, DNA-binding domain and the hinge region to human <inline-formula><mml:math id="m80"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> ligand-binding domain. The chimeric GFP-tagged receptor was stably expressed in MCF7 Tet-off Advanced cell line (Clontech). Cells plated in duplicates on a 384-well plate were treated with compounds or a diluent as control for 3 h, fixed with paraformaldehyde, the nuclei stained with DRAQ5™ (abcam) or 4ʹ,6-diamindino-2-phenylindole (DAPI) and cells imaged on the PerkinElmer Opera quadruple-enhanced high-sensitivity high-content screening platform with fully automated confocal image collection. An image analysis pipeline was customized using the Columbus software (PerkinElmer) to automatically segment the nucleus using the DAPI channel and then construct a ring region (cytoplasm) around the nucleus mask for each cell in the digital micrographs. Translocation was calculated as a ratio of the mean <inline-formula><mml:math id="m81"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> intensity in nucleus and cytoplasm, and each value was further normalized to the value for the control (i.e., DMSO) sample on the same plate.</p>
    </sec>
    <sec id="s2.3">
      <title>Data Analysis for Tox21 Assay Data</title>
      <p>Each chemical in the qHTS assays from Tox21 was tested independently three times, with internal replication of chemicals with multiple samples in the library using 15-concentrations (for GH3-TRE-Luc assays) or 11-concentrations (for the mammalian one-hybrid BLA assays and coactivator recruitment assays). The data set was then corrected using an in-house pattern correction algorithm and normalized to controls (<xref rid="c90" ref-type="bibr">Wang and Huang 2016</xref>). Curve-fitting and hit-calling on the corrected data used the U.S. EPA’s ToxCast data pipeline (tcpl) (tcpl R package, version 1.2.2) (<xref rid="c23" ref-type="bibr">Filer et al. 2017</xref>). Curve-fitting based on the winning model (gain-loss, Hill, or constant) is summarized in level 5 of the ToxCast database, invitrodb_v2, including values such as the hit call (hitc), 50% activity concentration (<inline-formula><mml:math id="m82"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) and maximum efficacy expressed as a percent of the positive control response (EMax). A positive hitc (<inline-formula><mml:math id="m83"><mml:mrow><mml:mtext>hitc</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>) indicates that the top of the winning model for curve surpassed the user-defined cutoff for minimum efficacy to be called a positive. The cutoff for these assays was defined statistically as the greater of six times baseline median absolute deviation (bmad) or a 20% change from control. The bmad, cutoff, number of tested chemicals as defined by a chemical identification (chid), and the resultant active number and active percent in the assay are summarized in Excel Table S1. Results were reviewed for potentially bad curve fits, primarily keyed by the data quality flags accompanying the tcpl analysis, and hitc and <inline-formula><mml:math id="m84"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> adjusted manually, if required. Inactive samples were arbitrarily set to <inline-formula><mml:math id="m85"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1,000</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>, and the resulting data set was used for analysis. For the TR assays in agonist mode, <inline-formula><mml:math id="m86"><mml:mrow><mml:mn>1</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> T3 was the positive control and DMSO the neutral control. For the TR assays in antagonist mode, <inline-formula><mml:math id="m87"><mml:mrow><mml:mn>1</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> T3 was the neutral control and DMSO the positive control, that is, DMSO vehicle defined the minimum response in the assay. The complete tcpl curve-fitting results as well as manual review for the qHTS agonist, antagonist, and corresponding cell viability assays are presented in Excel Table S2 and follow-up transactivation assays in Excel Table S3. For the RXR agonist assays, <inline-formula><mml:math id="m88"><mml:mrow><mml:mn>5</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula> 9-<italic>cis</italic> retinoic acid was used as the positive control and DMSO as the neutral control. For the RXR antagonist assays, <inline-formula><mml:math id="m89"><mml:mrow><mml:mn>100</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> 9-<italic>cis</italic> retinoic acid was used as the neutral control and DMSO was used to define the minimum response in the assay. Data output from tcpl was than combined and summarized at the chemical level where multiple samples of the same chemical structure were present. All source data are available from the iCSS ToxCast dashboard version 2 (<ext-link ext-link-type="uri" xlink:href="https://comptox.epa.gov/dashboard">https://comptox.epa.gov/dashboard</ext-link>) and the invitrodb_v2 database (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.23645/epacomptox.6062623.v1">https://doi.org/10.23645/epacomptox.6062623.v1</ext-link>).</p>
    </sec>
    <sec id="s2.4">
      <title>Additional Context for Curating TR Agonists and Antagonists</title>
      <p><bold><italic>Cell viability analysis.</italic></bold> Eighteen cell viability assays using different technologies and cell types were performed on the Tox21 library compounds as part of the Tox21 project (<xref rid="c40" ref-type="bibr">Judson et al. 2016</xref>) (see Excel Table S4). The percentage resulting in <inline-formula><mml:math id="m90"><mml:mrow><mml:mtext>hitc</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and the median and lowest <inline-formula><mml:math id="m91"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> were determined. These results were used with the other assay results described here in a weight-of-evidence approach to help with selecting candidate TR antagonists for follow-up testing.</p>
      <p><bold><italic>Tanimoto similarity score on indigo fingerprints.</italic></bold> All compounds identified as agonists were searched using batch mode against the 761,000 structures in the U.S. EPA CompTox Chemicals Dashboard to identify structurally similar compounds (<ext-link ext-link-type="uri" xlink:href="https://comptox.epa.gov/dashboard/dsstoxdb/batch_search">https://comptox.epa.gov/dashboard/dsstoxdb/batch_search</ext-link>). Similarity is based on a Tanimoto score derived from Indigo Toolkit structural fingerprints using the 1.7.10-dev6.3 linux64 version of the Bingo PostgreSQL Cartridge with the default Indigo fingerprint (<ext-link ext-link-type="uri" xlink:href="http://lifescience.opensource.epam.com/indigo/">http://lifescience.opensource.epam.com/indigo/</ext-link>). The similarity search tool returned 130 compounds with a Tanimoto score of <inline-formula><mml:math id="m92"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>. The CAS registration number (CASRN) for these compounds was used to query the Tox21 chemical library to identify potential false negatives from the qHTS assay. The three compounds with the highest confidence results for antagonists were also searched in DSSTox for related substances. There were 204 compounds found with Tanimoto scores <inline-formula><mml:math id="m93"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>; however, none were included in the Tox21 screening library.</p>
      <p><bold><italic>Active rate comparison between receptors.</italic></bold> To compare active calls between receptors, we compared a subset of the Tox21 library chemicals screened in multiple estrogen receptor and androgen receptor assays that were used to build predictive systems biology models for agonist and antagonist modes, known as the ToxCast pathway models (<xref rid="c41" ref-type="bibr">Judson et al. 2015</xref>; <xref rid="c45" ref-type="bibr">Kleinstreuer et al. 2017</xref>). We first removed chemicals classified as pharmaceuticals because these sets of chemicals are biased toward drugs targeting estrogen receptors and androgen receptors. We then used the recommended model values of <inline-formula><mml:math id="m94"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></inline-formula> to define actives for both receptors and both modes. For TR, we cross-referenced these same chemicals for testing against TR and used candidate chemicals in <xref rid="t2" ref-type="table">Tables 2</xref> and <xref rid="t3" ref-type="table">3</xref> to define active rates.</p>
      <table-wrap id="t2" orientation="portrait" position="float">
        <label>Table 2</label>
        <caption>
          <p>Activities associated with agonist active chemicals.</p>
        </caption>
        <alt-text>Table 2 lists chemical name in the first column; the corresponding values for GH3-TRE-Ag AC50 (micromolar), GH3-TRE-Ag-Followup AC50 (micromolar), TRa-coa-Ag AC50 (micromolar), TRb-coa-Ag AC50 (micromolar), TRb-bla-Ag AC50 (micromolar), RXRa-bla-Ag AC50 (micromolar), GH3-TRE-Via AC50 (micromolar), and Global Cytotoxicity AC50 Median (micromolar), and its classification are listed in the other columns.</alt-text>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" id="t2c1" scope="col" rowspan="1" colspan="1">Chemical name</th>
              <th align="center" id="t2c2" scope="col" rowspan="1" colspan="1">GH3-TRE-Ag AC50 (<inline-formula><mml:math id="m95"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c3" scope="colgroup" rowspan="1" colspan="1">GH3-TRE-Ag-Followup AC50 (<inline-formula><mml:math id="m96"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c4" scope="col" rowspan="1" colspan="1">TRa-coa-Ag AC50 (<inline-formula><mml:math id="m97"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c5" scope="col" rowspan="1" colspan="1">TRb-coa-Ag AC50 (<inline-formula><mml:math id="m98"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c6" scope="col" rowspan="1" colspan="1">TRb-bla-Ag AC50 (<inline-formula><mml:math id="m99"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c7" scope="col" rowspan="1" colspan="1">RXRa-bla-Ag AC50 (<inline-formula><mml:math id="m100"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c8" scope="col" rowspan="1" colspan="1">GH3-TRE-Via AC50 (<inline-formula><mml:math id="m101"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c9" scope="col" rowspan="1" colspan="1">Global cytotoxicity AC50 median (<inline-formula><mml:math id="m102"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t2c10" scope="col" rowspan="1" colspan="1">Classification</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" id="t2c11" scope="row" headers="t2c1" rowspan="1" colspan="1">CP-634384</td>
              <td align="char" char="." headers="t2c2 t2c11" rowspan="1" colspan="1">0.0015</td>
              <td align="char" char="." headers="t2c3 t2c11" rowspan="1" colspan="1">0.0180</td>
              <td align="char" char="." headers="t2c4 t2c11" rowspan="1" colspan="1">0.0029</td>
              <td align="char" char="." headers="t2c5 t2c11" rowspan="1" colspan="1">0.0020</td>
              <td align="char" char="." headers="t2c6 t2c11" rowspan="1" colspan="1">0.0865</td>
              <td align="char" char="." headers="t2c7 t2c11" rowspan="1" colspan="1">44.299</td>
              <td align="char" char="." headers="t2c8 t2c11" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m103">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c11" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m104">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c11" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c12" scope="row" headers="t2c1" rowspan="1" colspan="1">3,5,3ʹ-Triiodothyronine</td>
              <td align="char" char="." headers="t2c2 t2c12" rowspan="1" colspan="1">0.0011</td>
              <td align="char" char="." headers="t2c3 t2c12" rowspan="1" colspan="1">0.0007</td>
              <td align="char" char="." headers="t2c4 t2c12" rowspan="1" colspan="1">0.0034</td>
              <td align="char" char="." headers="t2c5 t2c12" rowspan="1" colspan="1">0.0034</td>
              <td align="char" char="." headers="t2c6 t2c12" rowspan="1" colspan="1">0.0009</td>
              <td align="char" char="." headers="t2c7 t2c12" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m105">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c8 t2c12" rowspan="1" colspan="1">41.687</td>
              <td align="char" char="." headers="t2c9 t2c12" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m106">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c12" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c13" scope="row" headers="t2c1" rowspan="1" colspan="1">Levothyroxine</td>
              <td align="char" char="." headers="t2c2 t2c13" rowspan="1" colspan="1">0.0061</td>
              <td align="char" char="." headers="t2c3 t2c13" rowspan="1" colspan="1">0.0075</td>
              <td align="char" char="." headers="t2c4 t2c13" rowspan="1" colspan="1">0.0340</td>
              <td align="char" char="." headers="t2c5 t2c13" rowspan="1" colspan="1">0.1390</td>
              <td align="char" char="." headers="t2c6 t2c13" rowspan="1" colspan="1">0.0361</td>
              <td align="char" char="." headers="t2c7 t2c13" rowspan="1" colspan="1">1.3624</td>
              <td align="char" char="." headers="t2c8 t2c13" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m107">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c13" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m108">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c13" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c14" scope="row" headers="t2c1" rowspan="1" colspan="1">Tetrac</td>
              <td align="char" char="." headers="t2c2 t2c14" rowspan="1" colspan="1">0.0009</td>
              <td align="char" char="." headers="t2c3 t2c14" rowspan="1" colspan="1">0.0060</td>
              <td align="char" char="." headers="t2c4 t2c14" rowspan="1" colspan="1">0.2484</td>
              <td align="char" char="." headers="t2c5 t2c14" rowspan="1" colspan="1">0.2266</td>
              <td align="char" char="." headers="t2c6 t2c14" rowspan="1" colspan="1">0.0209</td>
              <td align="char" char="." headers="t2c7 t2c14" rowspan="1" colspan="1">23.551</td>
              <td align="char" char="." headers="t2c8 t2c14" rowspan="1" colspan="1">51.286</td>
              <td align="char" char="." headers="t2c9 t2c14" rowspan="1" colspan="1">35.7</td>
              <td align="center" headers="t2c10 t2c14" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c15" scope="row" headers="t2c1" rowspan="1" colspan="1">3,3ʹ,5ʹ-Triiodo-<sc>l</sc>-thyronine</td>
              <td align="char" char="." headers="t2c2 t2c15" rowspan="1" colspan="1">0.2183</td>
              <td align="char" char="." headers="t2c3 t2c15" rowspan="1" colspan="1">0.5373</td>
              <td align="char" char="." headers="t2c4 t2c15" rowspan="1" colspan="1">0.7065</td>
              <td align="char" char="." headers="t2c5 t2c15" rowspan="1" colspan="1">1.0002</td>
              <td align="char" char="." headers="t2c6 t2c15" rowspan="1" colspan="1">0.6415</td>
              <td align="char" char="." headers="t2c7 t2c15" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t2c8 t2c15" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m109">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c15" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m110">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c15" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c16" scope="row" headers="t2c1" rowspan="1" colspan="1">Tiratricol</td>
              <td align="char" char="." headers="t2c2 t2c16" rowspan="1" colspan="1">0.000010</td>
              <td align="char" char="." headers="t2c3 t2c16" rowspan="1" colspan="1">0.0002</td>
              <td align="char" char="." headers="t2c4 t2c16" rowspan="1" colspan="1">0.0057</td>
              <td align="char" char="." headers="t2c5 t2c16" rowspan="1" colspan="1">0.0047</td>
              <td align="char" char="." headers="t2c6 t2c16" rowspan="1" colspan="1">0.0005</td>
              <td align="char" char="." headers="t2c7 t2c16" rowspan="1" colspan="1">7.872</td>
              <td align="char" char="." headers="t2c8 t2c16" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m111">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c16" rowspan="1" colspan="1">27.0</td>
              <td align="center" headers="t2c10 t2c16" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c17" scope="row" headers="t2c1" rowspan="1" colspan="1">3,3ʹ,5-Triiodo-<sc>l</sc>-thyronine sodium salt</td>
              <td align="char" char="." headers="t2c2 t2c17" rowspan="1" colspan="1">0.0002</td>
              <td align="char" char="." headers="t2c3 t2c17" rowspan="1" colspan="1">0.0021</td>
              <td align="char" char="." headers="t2c4 t2c17" rowspan="1" colspan="1">0.0133</td>
              <td align="char" char="." headers="t2c5 t2c17" rowspan="1" colspan="1">0.0126</td>
              <td align="char" char="." headers="t2c6 t2c17" rowspan="1" colspan="1">0.0036</td>
              <td align="char" char="." headers="t2c7 t2c17" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m112">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c8 t2c17" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m113">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c17" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m114">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c17" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c18" scope="row" headers="t2c1" rowspan="1" colspan="1">Betamipron</td>
              <td align="char" char="." headers="t2c2 t2c18" rowspan="1" colspan="1">11.8412</td>
              <td align="char" char="." headers="t2c3 t2c18" rowspan="1" colspan="1">1.6786</td>
              <td align="char" char="." headers="t2c4 t2c18" rowspan="1" colspan="1">10.403</td>
              <td align="char" char="." headers="t2c5 t2c18" rowspan="1" colspan="1">11.765</td>
              <td align="char" char="." headers="t2c6 t2c18" rowspan="1" colspan="1">14.030</td>
              <td align="char" char="." headers="t2c7 t2c18" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m115">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c8 t2c18" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m116">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c18" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m117">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c18" rowspan="1" colspan="1">TR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c19" scope="row" headers="t2c1" rowspan="1" colspan="1">all <italic>trans</italic>-Retinoic acid</td>
              <td align="char" char="." headers="t2c2 t2c19" rowspan="1" colspan="1">0.2336</td>
              <td align="char" char="." headers="t2c3 t2c19" rowspan="1" colspan="1">1.1589</td>
              <td align="char" char="." headers="t2c3 t2c19" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m118">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c19" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m119">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c6 t2c19" rowspan="1" colspan="1">1.480</td>
              <td align="char" char="." headers="t2c7 t2c19" rowspan="1" colspan="1">0.7878</td>
              <td align="char" char="." headers="t2c8 t2c19" rowspan="1" colspan="1">66.737</td>
              <td align="char" char="." headers="t2c9 t2c19" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m120">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c19" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c20" scope="row" headers="t2c1" rowspan="1" colspan="1">(Acryloyloxy)(tributyl)stannane</td>
              <td align="char" char="." headers="t2c2 t2c20" rowspan="1" colspan="1">0.07351</td>
              <td align="char" char="." headers="t2c3 t2c20" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m121">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c3 t2c20" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m122">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c20" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m123">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c6 t2c20" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m124">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c20" rowspan="1" colspan="1">0.1410</td>
              <td align="char" char="." headers="t2c8 t2c20" rowspan="1" colspan="1">0.508</td>
              <td align="char" char="." headers="t2c9 t2c20" rowspan="1" colspan="1">1.0</td>
              <td align="center" headers="t2c10 t2c20" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c21" scope="row" headers="t2c1" rowspan="1" colspan="1">Acitretin</td>
              <td align="char" char="." headers="t2c2 t2c21" rowspan="1" colspan="1">4.3272</td>
              <td align="char" char="." headers="t2c3 t2c21" rowspan="1" colspan="1">0.9399</td>
              <td align="char" char="." headers="t2c3 t2c21" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m125">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c21" rowspan="1" colspan="1">9.701</td>
              <td align="char" char="." headers="t2c6 t2c21" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m126">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c21" rowspan="1" colspan="1">0.5639</td>
              <td align="char" char="." headers="t2c8 t2c21" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m127">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c21" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m128">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c21" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c22" scope="row" headers="t2c1" rowspan="1" colspan="1">13-<italic>cis</italic> Retinoic acid</td>
              <td align="char" char="." headers="t2c2 t2c22" rowspan="1" colspan="1">0.1328</td>
              <td align="char" char="." headers="t2c3 t2c22" rowspan="1" colspan="1">0.0348</td>
              <td align="char" char="." headers="t2c3 t2c22" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m129">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c22" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m130">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c6 t2c22" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m131">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c22" rowspan="1" colspan="1">0.0236</td>
              <td align="char" char="." headers="t2c8 t2c22" rowspan="1" colspan="1">81.283</td>
              <td align="char" char="." headers="t2c9 t2c22" rowspan="1" colspan="1">46.3</td>
              <td align="center" headers="t2c10 t2c22" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c23" scope="row" headers="t2c1" rowspan="1" colspan="1">9-<italic>cis</italic> Retinoic acid</td>
              <td align="char" char="." headers="t2c2 t2c23" rowspan="1" colspan="1">4.1796</td>
              <td align="char" char="." headers="t2c3 t2c23" rowspan="1" colspan="1">2.0677</td>
              <td align="char" char="." headers="t2c3 t2c23" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m132">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c23" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m133">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c6 t2c23" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m134">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c23" rowspan="1" colspan="1">1.848</td>
              <td align="char" char="." headers="t2c8 t2c23" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m135">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c23" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m136">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c23" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c24" scope="row" headers="t2c1" rowspan="1" colspan="1">Sincalide</td>
              <td align="char" char="." headers="t2c2 t2c24" rowspan="1" colspan="1">12.376</td>
              <td align="char" char="." headers="t2c3 t2c24" rowspan="1" colspan="1">8.588</td>
              <td align="char" char="." headers="t2c3 t2c24" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m137">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c24" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m138">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c6 t2c24" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m139">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c24" rowspan="1" colspan="1">10.496</td>
              <td align="char" char="." headers="t2c8 t2c24" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m140">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c9 t2c24" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m141">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c24" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c25" scope="row" headers="t2c1" rowspan="1" colspan="1">Clofoctol</td>
              <td align="char" char="." headers="t2c2 t2c25" rowspan="1" colspan="1">1.374</td>
              <td align="char" char="." headers="t2c3 t2c25" rowspan="1" colspan="1">3.004</td>
              <td align="char" char="." headers="t2c3 t2c25" rowspan="1" colspan="1">8.920</td>
              <td align="char" char="." headers="t2c5 t2c25" rowspan="1" colspan="1">8.928</td>
              <td align="char" char="." headers="t2c6 t2c25" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m142">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c25" rowspan="1" colspan="1">6.796</td>
              <td align="char" char="." headers="t2c8 t2c25" rowspan="1" colspan="1">8.035</td>
              <td align="char" char="." headers="t2c9 t2c25" rowspan="1" colspan="1">16.7</td>
              <td align="center" headers="t2c10 t2c25" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c26" scope="row" headers="t2c1" rowspan="1" colspan="1">Bexarotene</td>
              <td align="char" char="." headers="t2c2 t2c26" rowspan="1" colspan="1">0.0077</td>
              <td align="char" char="." headers="t2c3 t2c26" rowspan="1" colspan="1">0.0170</td>
              <td align="char" char="." headers="t2c3 t2c26" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m143">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c26" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m144">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c6 t2c26" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m145">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c26" rowspan="1" colspan="1">0.0053</td>
              <td align="char" char="." headers="t2c8 t2c26" rowspan="1" colspan="1">10.351</td>
              <td align="char" char="." headers="t2c9 t2c26" rowspan="1" colspan="1">23.9</td>
              <td align="center" headers="t2c10 t2c26" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
            <tr>
              <td align="left" id="t2c27" scope="row" headers="t2c1" rowspan="1" colspan="1">Equilin</td>
              <td align="char" char="." headers="t2c2 t2c27" rowspan="1" colspan="1">3.4083</td>
              <td align="char" char="." headers="t2c3 t2c27" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m146">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c3 t2c27" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m147">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c5 t2c27" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m148">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c6 t2c27" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m149">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="char" char="." headers="t2c7 t2c27" rowspan="1" colspan="1">0.9860</td>
              <td align="char" char="." headers="t2c8 t2c27" rowspan="1" colspan="1">85.114</td>
              <td align="char" char="." headers="t2c9 t2c27" rowspan="1" colspan="1">
                <inline-formula>
                  <mml:math id="m150">
                    <mml:mrow>
                      <mml:mo>&gt;</mml:mo>
                      <mml:mn>92</mml:mn>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td align="center" headers="t2c10 t2c27" rowspan="1" colspan="1">RXR-Ag</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TF2">
            <p>Note: AC50, concentration producing 50% activation of the receptor; Ag, agonist; bla, beta-lactamase; coa, coactivator; GH3, rat pituitary cell line; RXRa, retinoid X receptor alpha; TR, thyroid hormone receptor; TRa, thyroid hormone receptor alpha; TRb, thyroid hormone receptor beta; TRE, thyroid hormone receptor response element; Via, viability.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="t3" orientation="portrait" position="float">
        <label>Table 3</label>
        <caption>
          <p>Activities associated with antagonist active chemicals.</p>
        </caption>
        <alt-text>Table 3 lists chemical name in the first column; the corresponding values for GH3-TRE-Ag AC50 (micromolar), GH3-TRE-Antag AC50 (micromolar), GH3-TRE-Via AC50 (micromolar), viability/antagonist ratio, global cytotoxicity AC50 median (micromolar), percentage active in global cytotoxicity assays, average cell number/field in nuclear translocation assay, and nuclear to cytoplasm ratio (EMax) are listed in the other columns.</alt-text>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
            <col align="left" valign="top" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" id="t3c1" scope="col" rowspan="1" colspan="1">Chemical name</th>
              <th align="center" id="t3c2" scope="col" rowspan="1" colspan="1">GH3-TRE-Ag AC50 (<inline-formula><mml:math id="m151"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t3c3" scope="col" rowspan="1" colspan="1">GH3-TRE-Antag AC50 (<inline-formula><mml:math id="m152"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t3c4" scope="col" rowspan="1" colspan="1">GH3-TRE-Via AC50 (<inline-formula><mml:math id="m153"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t3c5" scope="col" rowspan="1" colspan="1">Viability/antagonist ratio</th>
              <th align="center" id="t3c6" scope="col" rowspan="1" colspan="1">Global cytotoxicity AC50 median (<inline-formula><mml:math id="m154"><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>)</th>
              <th align="center" id="t3c7" scope="col" rowspan="1" colspan="1">Active in global cytotoxicity assays (%)</th>
              <th align="center" id="t3c8" scope="col" rowspan="1" colspan="1">Average cell number/field in nuclear translocation assay</th>
              <th align="center" id="t3c9" scope="col" rowspan="1" colspan="1">Nuclear/cytoplasm ratio (EMax)</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" id="t3c10" scope="row" headers="t3c1" rowspan="1" colspan="1">Mefenamic acid</td>
              <td align="char" char="." headers="t3c2 t3c10" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c10" rowspan="1" colspan="1">19.50</td>
              <td align="char" char="." headers="t3c4 t3c10" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c5 t3c10" rowspan="1" colspan="1">51.3</td>
              <td align="char" char="." headers="t3c6 t3c10" rowspan="1" colspan="1">50.80</td>
              <td align="char" char="." headers="t3c7 t3c10" rowspan="1" colspan="1">4.5</td>
              <td align="char" char="." headers="t3c8 t3c10" rowspan="1" colspan="1">2,472</td>
              <td align="char" char="." headers="t3c9 t3c10" rowspan="1" colspan="1">3.38</td>
            </tr>
            <tr>
              <td align="left" id="t3c11" scope="row" headers="t3c1" rowspan="1" colspan="1">Risarestat</td>
              <td align="char" char="." headers="t3c2 t3c11" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c11" rowspan="1" colspan="1">5.63</td>
              <td align="char" char="." headers="t3c4 t3c11" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c5 t3c11" rowspan="1" colspan="1">177.6</td>
              <td align="char" char="." headers="t3c6 t3c11" rowspan="1" colspan="1">16.36</td>
              <td align="char" char="." headers="t3c7 t3c11" rowspan="1" colspan="1">11.9</td>
              <td align="char" char="." headers="t3c8 t3c11" rowspan="1" colspan="1">2,349</td>
              <td align="char" char="." headers="t3c9 t3c11" rowspan="1" colspan="1">3.31</td>
            </tr>
            <tr>
              <td align="left" id="t3c12" scope="row" headers="t3c1" rowspan="1" colspan="1">Carfilzomib</td>
              <td align="char" char="." headers="t3c2 t3c12" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c12" rowspan="1" colspan="1">0.025</td>
              <td align="char" char="." headers="t3c4 t3c12" rowspan="1" colspan="1">0.037</td>
              <td align="char" char="." headers="t3c5 t3c12" rowspan="1" colspan="1">1.5</td>
              <td align="char" char="." headers="t3c6 t3c12" rowspan="1" colspan="1">0.46</td>
              <td align="char" char="." headers="t3c7 t3c12" rowspan="1" colspan="1">64.4</td>
              <td align="char" char="." headers="t3c8 t3c12" rowspan="1" colspan="1">1,642</td>
              <td align="char" char="." headers="t3c9 t3c12" rowspan="1" colspan="1">3.28</td>
            </tr>
            <tr>
              <td align="left" id="t3c13" scope="row" headers="t3c1" rowspan="1" colspan="1">Diclazuril</td>
              <td align="char" char="." headers="t3c2 t3c13" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c13" rowspan="1" colspan="1">4.70</td>
              <td align="char" char="." headers="t3c4 t3c13" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c5 t3c13" rowspan="1" colspan="1">212.8</td>
              <td align="char" char="." headers="t3c6 t3c13" rowspan="1" colspan="1">32.98</td>
              <td align="char" char="." headers="t3c7 t3c13" rowspan="1" colspan="1">33.3</td>
              <td align="char" char="." headers="t3c8 t3c13" rowspan="1" colspan="1">2,608</td>
              <td align="char" char="." headers="t3c9 t3c13" rowspan="1" colspan="1">2.69</td>
            </tr>
            <tr>
              <td align="left" id="t3c14" scope="row" headers="t3c1" rowspan="1" colspan="1">Omacetaxine mepesuccinate</td>
              <td align="char" char="." headers="t3c2 t3c14" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c14" rowspan="1" colspan="1">0.029</td>
              <td align="char" char="." headers="t3c4 t3c14" rowspan="1" colspan="1">0.057</td>
              <td align="char" char="." headers="t3c5 t3c14" rowspan="1" colspan="1">2.0</td>
              <td align="char" char="." headers="t3c6 t3c14" rowspan="1" colspan="1">0.06</td>
              <td align="char" char="." headers="t3c7 t3c14" rowspan="1" colspan="1">60.0</td>
              <td align="char" char="." headers="t3c8 t3c14" rowspan="1" colspan="1">1,601</td>
              <td align="char" char="." headers="t3c9 t3c14" rowspan="1" colspan="1">1.74</td>
            </tr>
            <tr>
              <td align="left" id="t3c15" scope="row" headers="t3c1" rowspan="1" colspan="1">Daunorubicin</td>
              <td align="char" char="." headers="t3c2 t3c15" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c15" rowspan="1" colspan="1">0.700</td>
              <td align="char" char="." headers="t3c4 t3c15" rowspan="1" colspan="1">1.01</td>
              <td align="char" char="." headers="t3c5 t3c15" rowspan="1" colspan="1">1.4</td>
              <td align="char" char="." headers="t3c6 t3c15" rowspan="1" colspan="1">10.46</td>
              <td align="char" char="." headers="t3c7 t3c15" rowspan="1" colspan="1">66.1</td>
              <td align="char" char="." headers="t3c8 t3c15" rowspan="1" colspan="1">224</td>
              <td align="char" char="." headers="t3c9 t3c15" rowspan="1" colspan="1">1.85</td>
            </tr>
            <tr>
              <td align="left" id="t3c16" scope="row" headers="t3c1" rowspan="1" colspan="1">1-Dodecyl-3-methylimidazolium iodide</td>
              <td align="char" char="." headers="t3c2 t3c16" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c16" rowspan="1" colspan="1">1.33</td>
              <td align="char" char="." headers="t3c4 t3c16" rowspan="1" colspan="1">5.10</td>
              <td align="char" char="." headers="t3c5 t3c16" rowspan="1" colspan="1">3.8</td>
              <td align="char" char="." headers="t3c6 t3c16" rowspan="1" colspan="1">41.10</td>
              <td align="char" char="." headers="t3c7 t3c16" rowspan="1" colspan="1">74.2</td>
              <td align="char" char="." headers="t3c8 t3c16" rowspan="1" colspan="1">282</td>
              <td align="char" char="." headers="t3c9 t3c16" rowspan="1" colspan="1">1.71</td>
            </tr>
            <tr>
              <td align="left" id="t3c17" scope="row" headers="t3c1" rowspan="1" colspan="1">Manidipine dihydrochloride</td>
              <td align="char" char="." headers="t3c2 t3c17" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c17" rowspan="1" colspan="1">7.40</td>
              <td align="char" char="." headers="t3c4 t3c17" rowspan="1" colspan="1">9.06</td>
              <td align="char" char="." headers="t3c5 t3c17" rowspan="1" colspan="1">1.2</td>
              <td align="char" char="." headers="t3c6 t3c17" rowspan="1" colspan="1">18.62</td>
              <td align="char" char="." headers="t3c7 t3c17" rowspan="1" colspan="1">28.8</td>
              <td align="char" char="." headers="t3c8 t3c17" rowspan="1" colspan="1">2,325</td>
              <td align="char" char="." headers="t3c9 t3c17" rowspan="1" colspan="1">1.69</td>
            </tr>
            <tr>
              <td align="left" id="t3c18" scope="row" headers="t3c1" rowspan="1" colspan="1">4,4ʹ-Methylenebis(<italic>N,N</italic>-diglycidylaniline)</td>
              <td align="char" char="." headers="t3c2 t3c18" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c18" rowspan="1" colspan="1">8.03</td>
              <td align="char" char="." headers="t3c4 t3c18" rowspan="1" colspan="1">11.10</td>
              <td align="char" char="." headers="t3c5 t3c18" rowspan="1" colspan="1">1.4</td>
              <td align="char" char="." headers="t3c6 t3c18" rowspan="1" colspan="1">45.26</td>
              <td align="char" char="." headers="t3c7 t3c18" rowspan="1" colspan="1">59.1</td>
              <td align="char" char="." headers="t3c8 t3c18" rowspan="1" colspan="1">2,095</td>
              <td align="char" char="." headers="t3c9 t3c18" rowspan="1" colspan="1">1.69</td>
            </tr>
            <tr>
              <td align="left" id="t3c19" scope="row" headers="t3c1" rowspan="1" colspan="1">Amlodipine besylate</td>
              <td align="char" char="." headers="t3c2 t3c19" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c19" rowspan="1" colspan="1">4.56</td>
              <td align="char" char="." headers="t3c4 t3c19" rowspan="1" colspan="1">2.15</td>
              <td align="char" char="." headers="t3c5 t3c19" rowspan="1" colspan="1">0.5</td>
              <td align="center" headers="t3c6 t3c19" rowspan="1" colspan="1">NT</td>
              <td align="center" headers="t3c7 t3c19" rowspan="1" colspan="1">NT</td>
              <td align="char" char="." headers="t3c8 t3c19" rowspan="1" colspan="1">912</td>
              <td align="char" char="." headers="t3c9 t3c19" rowspan="1" colspan="1">1.68</td>
            </tr>
            <tr>
              <td align="left" id="t3c20" scope="row" headers="t3c1" rowspan="1" colspan="1">Methyl red</td>
              <td align="char" char="." headers="t3c2 t3c20" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c20" rowspan="1" colspan="1">8.79</td>
              <td align="char" char="." headers="t3c4 t3c20" rowspan="1" colspan="1">14.59</td>
              <td align="char" char="." headers="t3c5 t3c20" rowspan="1" colspan="1">1.7</td>
              <td align="char" char="." headers="t3c6 t3c20" rowspan="1" colspan="1">48.54</td>
              <td align="char" char="." headers="t3c7 t3c20" rowspan="1" colspan="1">48.5</td>
              <td align="char" char="." headers="t3c8 t3c20" rowspan="1" colspan="1">2,101</td>
              <td align="char" char="." headers="t3c9 t3c20" rowspan="1" colspan="1">1.68</td>
            </tr>
            <tr>
              <td align="left" id="t3c21" scope="row" headers="t3c1" rowspan="1" colspan="1">C.I. Basic Red 9 monohydrochloride</td>
              <td align="char" char="." headers="t3c2 t3c21" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c21" rowspan="1" colspan="1">5.15</td>
              <td align="char" char="." headers="t3c4 t3c21" rowspan="1" colspan="1">8.80</td>
              <td align="char" char="." headers="t3c5 t3c21" rowspan="1" colspan="1">1.7</td>
              <td align="char" char="." headers="t3c6 t3c21" rowspan="1" colspan="1">24.17</td>
              <td align="char" char="." headers="t3c7 t3c21" rowspan="1" colspan="1">66.7</td>
              <td align="char" char="." headers="t3c8 t3c21" rowspan="1" colspan="1">2,197</td>
              <td align="char" char="." headers="t3c9 t3c21" rowspan="1" colspan="1">1.67</td>
            </tr>
            <tr>
              <td align="left" id="t3c22" scope="row" headers="t3c1" rowspan="1" colspan="1">Fludarabine</td>
              <td align="char" char="." headers="t3c2 t3c22" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c22" rowspan="1" colspan="1">16.27</td>
              <td align="char" char="." headers="t3c4 t3c22" rowspan="1" colspan="1">22.31</td>
              <td align="char" char="." headers="t3c5 t3c22" rowspan="1" colspan="1">1.4</td>
              <td align="char" char="." headers="t3c6 t3c22" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c7 t3c22" rowspan="1" colspan="1">1.7</td>
              <td align="char" char="." headers="t3c8 t3c22" rowspan="1" colspan="1">1,546</td>
              <td align="char" char="." headers="t3c9 t3c22" rowspan="1" colspan="1">1.64</td>
            </tr>
            <tr>
              <td align="left" id="t3c23" scope="row" headers="t3c1" rowspan="1" colspan="1">Andrographolide</td>
              <td align="char" char="." headers="t3c2 t3c23" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c23" rowspan="1" colspan="1">24.61</td>
              <td align="char" char="." headers="t3c4 t3c23" rowspan="1" colspan="1">19.35</td>
              <td align="char" char="." headers="t3c5 t3c23" rowspan="1" colspan="1">0.8</td>
              <td align="center" headers="t3c6 t3c23" rowspan="1" colspan="1">NT</td>
              <td align="center" headers="t3c7 t3c23" rowspan="1" colspan="1">NT</td>
              <td align="char" char="." headers="t3c8 t3c23" rowspan="1" colspan="1">2,333</td>
              <td align="char" char="." headers="t3c9 t3c23" rowspan="1" colspan="1">1.64</td>
            </tr>
            <tr>
              <td align="left" id="t3c24" scope="row" headers="t3c1" rowspan="1" colspan="1">Tomelukast</td>
              <td align="char" char="." headers="t3c2 t3c24" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c24" rowspan="1" colspan="1">25.92</td>
              <td align="char" char="." headers="t3c4 t3c24" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c5 t3c24" rowspan="1" colspan="1">38.6</td>
              <td align="char" char="." headers="t3c6 t3c24" rowspan="1" colspan="1">14.44</td>
              <td align="char" char="." headers="t3c7 t3c24" rowspan="1" colspan="1">9.1</td>
              <td align="char" char="." headers="t3c8 t3c24" rowspan="1" colspan="1">2,178</td>
              <td align="char" char="." headers="t3c9 t3c24" rowspan="1" colspan="1">1.64</td>
            </tr>
            <tr>
              <td align="left" id="t3c25" scope="row" headers="t3c1" rowspan="1" colspan="1">(Z,E)-Diethylstilbestrol</td>
              <td align="char" char="." headers="t3c2 t3c25" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c25" rowspan="1" colspan="1">17.06</td>
              <td align="char" char="." headers="t3c4 t3c25" rowspan="1" colspan="1">12.20</td>
              <td align="char" char="." headers="t3c5 t3c25" rowspan="1" colspan="1">0.7</td>
              <td align="center" headers="t3c6 t3c25" rowspan="1" colspan="1">NT</td>
              <td align="center" headers="t3c7 t3c25" rowspan="1" colspan="1">NT</td>
              <td align="char" char="." headers="t3c8 t3c25" rowspan="1" colspan="1">2,398</td>
              <td align="char" char="." headers="t3c9 t3c25" rowspan="1" colspan="1">1.63</td>
            </tr>
            <tr>
              <td align="left" id="t3c26" scope="row" headers="t3c1" rowspan="1" colspan="1">Duloxetine hydrochloride</td>
              <td align="char" char="." headers="t3c2 t3c26" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c26" rowspan="1" colspan="1">6.22</td>
              <td align="char" char="." headers="t3c4 t3c26" rowspan="1" colspan="1">5.69</td>
              <td align="char" char="." headers="t3c5 t3c26" rowspan="1" colspan="1">0.9</td>
              <td align="center" headers="t3c6 t3c26" rowspan="1" colspan="1">NT</td>
              <td align="center" headers="t3c7 t3c26" rowspan="1" colspan="1">NT</td>
              <td align="char" char="." headers="t3c8 t3c26" rowspan="1" colspan="1">1,184</td>
              <td align="char" char="." headers="t3c9 t3c26" rowspan="1" colspan="1">1.53</td>
            </tr>
            <tr>
              <td align="left" id="t3c27" scope="row" headers="t3c1" rowspan="1" colspan="1">5,7-Dichloro-8-hydroxy-2-methylquinoline</td>
              <td align="char" char="." headers="t3c2 t3c27" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c27" rowspan="1" colspan="1">1.50</td>
              <td align="char" char="." headers="t3c4 t3c27" rowspan="1" colspan="1">1.56</td>
              <td align="char" char="." headers="t3c5 t3c27" rowspan="1" colspan="1">1.0</td>
              <td align="char" char="." headers="t3c6 t3c27" rowspan="1" colspan="1">13.62</td>
              <td align="char" char="." headers="t3c7 t3c27" rowspan="1" colspan="1">13.6</td>
              <td align="char" char="." headers="t3c8 t3c27" rowspan="1" colspan="1">1,071</td>
              <td align="char" char="." headers="t3c9 t3c27" rowspan="1" colspan="1">1.61</td>
            </tr>
            <tr>
              <td align="left" id="t3c28" scope="row" headers="t3c1" rowspan="1" colspan="1">Rosaramicin</td>
              <td align="char" char="." headers="t3c2 t3c28" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c28" rowspan="1" colspan="1">22.58</td>
              <td align="char" char="." headers="t3c4 t3c28" rowspan="1" colspan="1">24.43</td>
              <td align="char" char="." headers="t3c5 t3c28" rowspan="1" colspan="1">1.1</td>
              <td align="char" char="." headers="t3c6 t3c28" rowspan="1" colspan="1">26.84</td>
              <td align="char" char="." headers="t3c7 t3c28" rowspan="1" colspan="1">46.7</td>
              <td align="char" char="." headers="t3c8 t3c28" rowspan="1" colspan="1">1,824</td>
              <td align="char" char="." headers="t3c9 t3c28" rowspan="1" colspan="1">1.52</td>
            </tr>
            <tr>
              <td align="left" id="t3c29" scope="row" headers="t3c1" rowspan="1" colspan="1">AMI-193</td>
              <td align="char" char="." headers="t3c2 t3c29" rowspan="1" colspan="1">1,000</td>
              <td align="char" char="." headers="t3c3 t3c29" rowspan="1" colspan="1">15.84</td>
              <td align="char" char="." headers="t3c4 t3c29" rowspan="1" colspan="1">14.08</td>
              <td align="char" char="." headers="t3c5 t3c29" rowspan="1" colspan="1">0.9</td>
              <td align="center" headers="t3c6 t3c29" rowspan="1" colspan="1">NT</td>
              <td align="center" headers="t3c7 t3c29" rowspan="1" colspan="1">NT</td>
              <td align="char" char="." headers="t3c8 t3c29" rowspan="1" colspan="1">2,291</td>
              <td align="char" char="." headers="t3c9 t3c29" rowspan="1" colspan="1">1.50</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TF3">
            <p>Note: AC50, concentration producing 50% activation of the receptor; Ag, agonist; Antag, antagonist; EMax, maximal response value; GH3, rat pituitary cell line; NT, not tested; TRE, thyroid hormone receptor response element; Via, viability.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
  </sec>
  <sec id="s3">
    <title>Results</title>
    <sec id="s3.1">
      <title>Agonists</title>
      <p>Complete results from both GH3-TRE qHTS agonist, antagonist, and viability mode for the 8,305 compounds are provided in Excel Table S2. For the agonist mode, 35 active compounds were considered active (<inline-formula><mml:math id="m155"><mml:mrow><mml:mtext>hitc</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>) following the automated tcpl curve-fitting algorithm. We reviewed all 35 active fits manually to identify possible false positives resulting from obvious outlier data as well as potential false negatives among any other curves that had an inactive hitc (<inline-formula><mml:math id="m156"><mml:mrow><mml:mtext>hitc</mml:mtext><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>) but demonstrated an EMax of 50% or greater. This resulted in 28 confirmed active compounds ranging in potency from <inline-formula><mml:math id="m157"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> (lowest concentration tested) to <inline-formula><mml:math id="m158"><mml:mrow><mml:mn>667</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula> (see Excel Table S5). Together with some potential false negatives, these chemicals, totaling 84 in all, were screened for activity in a series of assays for confirmation in the GH3-TRE-Ag assay; specificity screening in the <inline-formula><mml:math id="m159"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T and <inline-formula><mml:math id="m160"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-UAS-bla</mml:mtext></mml:mrow></mml:math></inline-formula> HEK 293T mammalian one-hybrid assays; viability assays for the HEK293T parental cell line; and orthogonal screening in two TR:coactivator recruitment assays, TRa-coa and TRb-coa. Results, summarized in <xref rid="t2" ref-type="table">Table 2</xref>, with more details in Excel Table S6, showed 16 of the original active compounds repeated as actives in the GH3 assay, along with 5 additional compounds that originally had <inline-formula><mml:math id="m161"><mml:mrow><mml:mtext>hitc</mml:mtext><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> but significant efficacy. Behavior across the characterization assays showed that the compounds could be clustered into several mechanistic categories—full agonists, indirect TR agonists/RXR agonists, and weak/ambiguous actives—as described below.</p>
      <p><bold><italic>Full Agonists.</italic></bold> Eight compounds were active in all three of the TR transactivation assays, active in both coactivator recruitment assays, inactive in the RXR assay (or only showing weak activity at greater than a 5-fold higher concentration compared with TR), and no cytotoxicity was detected in the range of the reporter activity. The average EMax in the TR transactivation assays in the primary and follow-up GH3 assay for these full agonists (excluding tromethamine hydrochloride) was <inline-formula><mml:math id="m162"><mml:mrow><mml:mn>102</mml:mn><mml:mo>±</mml:mo><mml:mn>19</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> of the response of the positive control, T3. This supports full agonist pharmacological behavior at the receptor for these ligands. An example characteristic of results for a full agonist, betamipron, is shown in <xref ref-type="fig" rid="f1">Figure 1A</xref>. It showed concentration-dependent activity in the GH3-TRE-Luc assay as an agonist in the rat GH3 cell for TR, in the <inline-formula><mml:math id="m163"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-bla</mml:mtext></mml:mrow></mml:math></inline-formula> as an agonist for the human <inline-formula><mml:math id="m164"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> ligand-binding domain, in the TRa-coa and TRb-coa biochemical assays showing activation of receptor recruitment of coactivator peptide, and lack of activity against the human <inline-formula><mml:math id="m165"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> receptor assay. The structures of this group of full TR agonists are shown in Figure S2A and consist of known TR ligands T3 (3,5,3ʹ-triiodothyronine; two salt forms active); 3,3ʹ,5ʹ-triiodo-<sc>l</sc>-thyronine and the prohormone T4 (3,3ʹ,5,5ʹ-tetraiodothyroacetic acid); synthetic analogs levothyroxine and tiratricol; and an oxamic acid–derivative pharmaceutical compound, CP-634384, developed as a TR ligand (<xref rid="c81" ref-type="bibr">Stanton et al. 2000</xref>). The other compounds in this category are betamipron, a drug used to reduce nephrotoxicity by blocking kidney uptake of an antibiotic and not previously described as a TR agonist (<xref rid="c32" ref-type="bibr">Hirouchi et al. 1994</xref>) and tromethamine hydrochloride (structure not shown), an unexpected finding for a low-molecular-weight compound commonly employed as a biochemical buffer. The analytical chemistry quality control for the tromethamine hydrochloride sample was unavailable, but three samples of the free acid version of the compound, tromethamine (CASRN 77-86-1), were completely inactive in the original TR GH3 qHTS assay and each had confirmed structures with purity <inline-formula><mml:math id="m166"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>90</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>. Thus, the activity seen for tromethamine hydrochloride may be due to a contaminant of the sample with a potent TR agonist such as T3.</p>
      <fig id="f1" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Example characterization of thyroid hormone receptor (TR) agonists. Candidate TR agonists were tested in concentration–response format in three reporter gene assays: 1) TR_GH3, the rat pituitary cell line used in the qHTS; 2) <inline-formula><mml:math id="m167"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mo>_</mml:mo><mml:mtext>HEK</mml:mtext><mml:mn>293</mml:mn></mml:mrow></mml:math></inline-formula>, a mammalian one-hybrid format assay using the human <inline-formula><mml:math id="m168"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> ligand-binding domain and a <inline-formula><mml:math id="m169"><mml:mrow><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-lactamase</mml:mtext></mml:mrow></mml:math></inline-formula> reporter gene in HEK293 cells; and 3) RXR_HEK293, a mammalian one-hybrid format assay using the human <inline-formula><mml:math id="m170"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> ligand-binding domain and a <inline-formula><mml:math id="m171"><mml:mrow><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-lactamase</mml:mtext></mml:mrow></mml:math></inline-formula> reporter gene in HEK293 cells. The fourth assay, <inline-formula><mml:math id="m172"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mo>_</mml:mo><mml:mtext>SRC</mml:mtext><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, is a functional biochemical assay that measures the ligand-stimulated recruitment of a SRC2 peptide to human <inline-formula><mml:math id="m173"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> ligand-binding domain. Examples are provided for (A) a direct-acting agonist, betamipron, and (B) an indirect activator, 13-<italic>cis</italic> retinoic acid, working through RXR.</p>
        </caption>
        <alt-text>Figure 1A comprises four line graphs for a direct-acting agonist betamipron plotting percentage activity in the range of negative 50 to 150 in increments of 50 (y-axis) across log 10 concentration (micromolar) ranging from negative 3 to 1 in unit increments (x-axis), each for TR GH3, TRa coa and TRb coa, TRb BLA, and RXR BLA. Figure 1B comprises four line graphs for a direct-acting agonist 13-cis retinoic acid plotting percentage activity in the range of negative 50 to 150 in increments of 50 (y-axis) across log 10 concentration (micromolar) ranging from negative 3 to 1 in unit increments (x-axis), each for TR GH3, TRa coa and TRb coa, TRb BLA, and RXR BLA.</alt-text>
        <graphic xlink:href="ehp-127-097009-g0001"/>
      </fig>
      <p><bold><italic>Indirect TR Agonists/RXR Agonists.</italic></bold> Seven compounds were active in the GH3 assay but not in the TR assays in mammalian one-hybrid format nor in the TR coactivator recruitment assays. Results for the characterization of 13-<italic>cis</italic> retinoic acid are shown as a representative response in <xref ref-type="fig" rid="f1">Figure 1B</xref>. This chemical was a partial agonist in the GH3-TRE-Ag assay (EMax of 24% of control), not active in the <inline-formula><mml:math id="m174"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi><mml:mtext>-bla</mml:mtext></mml:mrow></mml:math></inline-formula> as an agonist for the human <inline-formula><mml:math id="m175"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> ligand-binding domain, not active in the TRb-coa biochemical assay, but active against the human <inline-formula><mml:math id="m176"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> receptor in the <inline-formula><mml:math id="m177"><mml:mrow><mml:mtext>RXR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi><mml:mtext>-bla-Ag</mml:mtext></mml:mrow></mml:math></inline-formula> assay. All of the active structures for this class are shown in Figure S2B. They had an average EMax value for the GH3 assay of <inline-formula><mml:math id="m178"><mml:mrow><mml:mn>45</mml:mn><mml:mo>±</mml:mo><mml:mn>26</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>. They were, however, active in the RXR transactivation assay and had average EMax values for RXR of <inline-formula><mml:math id="m179"><mml:mrow><mml:mn>75</mml:mn><mml:mo>±</mml:mo><mml:mn>28</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>. Several of these are synthetic rexinoids (bexarotene/Targretin®, 13-<italic>cis</italic> retinoic acid/Accutane®) or retinoids with known RXR activity (acitretin/Soriatane®, 9-<italic>cis</italic> retinoic acid/Panretin®, <italic>trans</italic>-retinoic acid/tretinoin). Sincalide, an 8-amino acid carboxy-terminal fragment of cholecystokinin also known as CCK-8, is not known as an RXR ligand and its structure is very distinct from known agonists. Analysis of other results from Tox21 screening assays showed it inactive against four other nuclear receptors but active for two estrogen receptor transactivation assays (<ext-link ext-link-type="uri" xlink:href="https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID7048617#">https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID7048617#</ext-link>). All in this group were inactive in the mammalian one-hybrid TR assays in which heterodimerization with RXR is not necessary for transcriptional activity. Thus, these appear to be RXR agonists acting at the TR response element in the GH3 assay through a permissive heterodimerization with TR, consistent with known pharmacology (<xref rid="c9" ref-type="bibr">Castillo et al. 2004</xref>).</p>
      <p><bold><italic>Weak/Ambiguous Actives.</italic></bold> There were 10 inactive compounds in most or all other characterization assays beyond TR-GH3 (see Figure S2C). These mostly had low EMax values with an average of <inline-formula><mml:math id="m180"><mml:mrow><mml:mn>32</mml:mn><mml:mo>±</mml:mo><mml:mn>11</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>. The data are inconclusive as to whether these represent very weak TR or RXR agonists, directly or indirectly, or an assay interference of unknown mechanism. One of these compounds, <italic>N,N</italic>-dimethyl-4-nitrosoaniline, was found to be a luciferase inhibitor, a mechanism that can paradoxically increase signal in luciferase reporter gene assays due to stabilization of the luciferase enzyme, although the lack of additional luciferase inhibitors behaving as agonists suggests this assay was not sensitive to such a mechanism (<xref rid="c84" ref-type="bibr">Thorne et al. 2010</xref>). Another, clofoctol, had activity in the coactivator recruitment assays and the RXR assay (although the EMax was only 36%) but not in the one-hybrid HEK293 assay for TR. It was also a promiscuous active in other Tox21 reporter gene assays. It is an older antibiotic but more recently found to inhibit prostate cancer cell growth, possibly through activation of the unfolded protein response pathway (<xref rid="c89" ref-type="bibr">Wang et al. 2014</xref>). Finally, glycocholic acid is a bile acid that was active in the GH3-TRE primary screen and follow-up and inactive in all the other assays. Interestingly, it was tested in over 200 other assays in the ToxCast and Tox21 programs and found active only in the GH3-TRE assay, a <inline-formula><mml:math id="m181"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> agonist assay run as part of a multiplexed transcription factor activation assay (ATG_THRa1_TRANS_up) and two estrogen receptor assays (ATG_ERE_CIS_up; TOX21_ERa_LUC_BG1_Agonist) (<ext-link ext-link-type="uri" xlink:href="https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID7048617#">https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID7048617#</ext-link>). The lack of activity in both the mammalian one-hybrid and the coactivator recruitment assays support this being a false positive of some type, but further investigation may be warranted.</p>
      <p>As a means of evaluating the potential of false-negative screening results for the agonists, we used structures of the confirmed agonists to query the 761,000 structures in the DSSTox database to identify similar structures by Tanimoto score (<inline-formula><mml:math id="m182"><mml:mrow><mml:mo>&gt;</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula>) based on Indigo Toolkit structure fingerprints. There were 130 new compounds identified (see Excel Table S7), but only one was included in the Tox21 library, 3,5-diiodo-<sc>l</sc>-tyrosine (CASRN 300-39-0), a precursor to thyroid hormone. It was completely inactive in the GH3-TRE assay. It had a high Tanimoto score (0.89) compared against 3-5-3ʹ-triidothyronine but lacks an entire phenol ring, which could readily explain lack of efficacy and/or affinity for TR. The DSSTox database consists of a compilation of existing lists of chemicals not only of environmental concern but also lists of compounds of interest for their bioactivity such as drugs and pharmacological probes from PubMed. Of the 130 similar compounds, only 16 were part of any of the lists specifically available on the CompTox Chemicals Dashboard (<ext-link ext-link-type="uri" xlink:href="https://comptox.epa.gov/dashboard/chemical_lists">https://comptox.epa.gov/dashboard/chemical_lists</ext-link>) that focuses on environmental chemical inventories.</p>
    </sec>
    <sec id="s3.2">
      <title>Antagonists</title>
      <p>The antagonist mode of the GH3-TRE assay was conducted under conditions where the reporter gene was activated with an approximate <inline-formula><mml:math id="m183"><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>85</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> (85% of maximal activity; <inline-formula><mml:math id="m184"><mml:mrow><mml:mn>1</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula>) of T3. There were 2,394 chemicals with active hit calls and calculated <inline-formula><mml:math id="m185"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> values, which were reduced to 2,375 by manual curve review (see Excel Table S8). A cell viability assay was run in parallel because of the known confounding problem of cytotoxicity resulting in false positives due to the loss-of-signal assay format (<xref rid="c16" ref-type="bibr">Crisman et al. 2007</xref>). Of the potential androgen receptor antagonists, 1,578 were also scored as cytotoxic in the concurrently run viability assay, 1,416 of these with less than 3-fold difference in <inline-formula><mml:math id="m186"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> in the two assays. Even with stringent rules such as requiring at least a 10-fold difference in the <inline-formula><mml:math id="m187"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> for antagonism versus cell viability, there were 812 potential TR antagonists, including compounds with well-known cytotoxic, cytostatic, or protein translation inhibition mechanisms of action. Topotecan hydrochloride, for example, a topoisomerase inhibitor and chemotherapeutic drug, showed complete inhibition of luciferase activity with an <inline-formula><mml:math id="m188"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> of <inline-formula><mml:math id="m189"><mml:mrow><mml:mn>2.4</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>. However, it was not considered active in the cell viability assay, similar to other Tox21 cell viability assays (see, for example, AID 743033 in PubChem, <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/bioassay/743033#section=Top">https://pubchem.ncbi.nlm.nih.gov/bioassay/743033#section=Top</ext-link>).</p>
      <p>To identify true antagonists of TR, we evaluated the ability of the candidate compounds to induce nuclear translocation of a green fluorescent protein (GFP)-tagged human <inline-formula><mml:math id="m190"><mml:mrow><mml:mtext>GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> hybrid receptor in MCF7 cells using the known TR antagonist, 1-850, as a positive control (<xref rid="c79" ref-type="bibr">Schapira et al. 2003</xref>). The GR sequence anchors the protein in the cytoplasm in the absence of ligand for TR. Both a potent natural agonist, T3, and the antagonist, 1-850, stimulated nuclear translocation/stabilization of the <inline-formula><mml:math id="m191"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula>, as shown in <xref ref-type="fig" rid="f2">Figure 2</xref>. We selected 285 compounds of the 699 candidate antagonists after initial filtering for cytotoxicity for testing in this assay. Selection was based on compound availability and potencies in the GH3-TRE-Antag assay while taking into account counter screening results for the GH3 cell viability assay, the cytotoxicity median <inline-formula><mml:math id="m192"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> value, and <italic>in vitro</italic> assay promiscuity rates in the nonviability Tox21 assays. Testing at a single, high concentration of <inline-formula><mml:math id="m193"><mml:mrow><mml:mn>50</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula> yielded 41 compounds that significantly increased nuclear translocation of the TR-GFP (<xref ref-type="fig" rid="f3">Figure 3</xref>). These were retested in a concentration–response format, and results are shown in <xref ref-type="fig" rid="f4">Figure 4</xref> and supporting data in Excel Table S9. Most showed activity only at the highest concentrations and the results were considered equivocal. All compounds were also screened at the highest concentration in the parental MCF7 cell line without the GFP fusion protein in order to test for potential false-positive effects due to compound fluorescence. The 41 compounds considered active in the translocation assay did not show any evidence of assay interference (see Excel Table S9).</p>
      <fig id="f2" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Stimulation of nuclear translocation of a <inline-formula><mml:math id="m194"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> fusion protein by thyroid hormone receptor (TR) agonists and antagonists. A human MCF7 breast cancer cell line mammary adenocarcinoma cell line that expresses <inline-formula><mml:math id="m195"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> was treated with the vehicle control [dimethyl sulfoxide (DMSO)], the positive agonist control triiodothyronine (T3) at <inline-formula><mml:math id="m196"><mml:mrow><mml:mn>100</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula>, or the antagonist control (1-850) at 25, 50, and <inline-formula><mml:math id="m197"><mml:mrow><mml:mn>100</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula> for 3 h followed by fixation, nuclear staining with DRAQ5™ (abcam) and imaging. An automated image analysis of localization was performed using the Opera (PerkinElmer) automated imaging system. (A) Representative images from the green fluorescent protein (GFP) channel, the DRAQ5™ channel, and an overlay for each of the treatments are shown. (B) Quantitation of the ratio of nuclear GFP to cytoplasmic GFP by imaging analysis. *, <inline-formula><mml:math id="m198"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
        </caption>
        <alt-text>Figure 2A comprises representative images from the GFP channel, the DRAQ5 channel, and an overlay for control treatment and treatments with 25 micromolar 1-850, 50 micromolar 1-850, 100 micromolar 1-850, and 100 nanomolar T3. Figure 2B is a bar graph plotting translocation (normalized to control) ranging from 0 to 6 in increments of 2 (y-axis) across the following treatments: DMSO, 25 micromolar 1-850, 50 micromolar 1-850, 100 micromolar 1-850, and 100 nanomolar T3 (x-axis).</alt-text>
        <graphic xlink:href="ehp-127-097009-g0002"/>
      </fig>
      <fig id="f3" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>Nuclear translocation assay screening of 285 candidate thyroid hormone receptor (TR) antagonists. A total of 285 compounds were evaluated in the <inline-formula><mml:math id="m199"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> translocation assay at a single concentration (<inline-formula><mml:math id="m200"><mml:mrow><mml:mn>100</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>). The positive control for translocation was triiodothyronine (T3) (<inline-formula><mml:math id="m201"><mml:mrow><mml:mn>100</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula>) (red squares). An algorithm for cytoplasm and nuclear segmentation of the cells was used to determine the mean <inline-formula><mml:math id="m202"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> intensity in both compartments, and translocation was quantified as a ratio of these intensities. Each value was normalized to the neutral control [dimethyl sulfoxide (DMSO)]. T3 produced a nuclear/cytoplasm ratio of 3, whereas inactive compounds were approximately 1. Several test compounds yielded similar results.</p>
        </caption>
        <alt-text>Figure 3 is a scatter plot plotting nuclear to cytoplasm GFP ratio (y-axis) ranging from 0 to 4 in unit increments across number of samples ranging from 0 to 300 in increments of 100 (x-axis) with for T3, diclazuril, risarestat, carfilzomib, and mefenamic acid labeled. Corresponding compound structures for diclazuril, risarestat, carfilzomib, and mefenamic acid are presented adjacent to the scatter plot.</alt-text>
        <graphic xlink:href="ehp-127-097009-g0003"/>
      </fig>
      <fig id="f4" orientation="portrait" position="float">
        <label>Figure 4.</label>
        <caption>
          <p>Multiple concentration testing of active compounds in the <inline-formula><mml:math id="m203"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> translocation assay. The 41 compounds identified as active in the single concentration screen were retested at four concentrations in the <inline-formula><mml:math id="m204"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> translocation assay. Data were analyzed and normalized as described in the text. Most compounds produced little or no concentration-dependent response. The ratio of the nuclear-to-cytoplasm fluorescence is presented in the heat map. The average cell number counted per well (10 images) is also indicated as a measure of potential cytotoxicity. Legends to each heat map are shown on the right. T3, triiodothyronine.</p>
        </caption>
        <alt-text>Figure 4 is a heat map showing cell numbers for the corresponding concentration of active compounds (micromolar) and their translocation ratio.</alt-text>
        <graphic xlink:href="ehp-127-097009-g0004"/>
      </fig>
      <p>The summary of results for the potential TR antagonists is provided in <xref rid="t3" ref-type="table">Table 3</xref>. Examples of the different classes of response are shown in <xref ref-type="fig" rid="f5">Figure 5</xref> for a likely false positive due to cytotoxicity (<xref ref-type="fig" rid="f5">Figure 5A</xref>), a probable false positive due to cytotoxicity but active in nuclear translocation (<xref ref-type="fig" rid="f5">Figure 5B</xref>), and a likely true antagonist (<xref ref-type="fig" rid="f5">Figure 5C)</xref>. None of the compounds identified as candidate antagonists had been previously characterized as direct TR antagonists. The most active, carfilzomib, is an irreversible proteasome inhibitor approved for chemotherapy of multiple myeloma. It showed an <inline-formula><mml:math id="m205"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> of <inline-formula><mml:math id="m206"><mml:mrow><mml:mn>25</mml:mn><mml:mtext>  nM</mml:mtext></mml:mrow></mml:math></inline-formula> for the GH3 assay for TR antagonist activity, similar to the active concentrations demonstrated for its proteasome inhibition and functional effects in myeloma cell lines (<xref rid="c50" ref-type="bibr">Kuhn et al. 2007</xref>). Carfilzomib is cytotoxic, active in 64% of Tox21 viability assays, and has a ratio of cell viability <inline-formula><mml:math id="m207"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> to GH3 transactivation <inline-formula><mml:math id="m208"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> of only 1.5. Thus, the effect in the translocation assay may be secondary to proteasome inhibition rather than direct TR activation. Another of the most active compounds in the nuclear translocation assay is mefenamic acid, a nonsteroidal inflammatory agent with very limited cytotoxicity in Tox21 assays (4.5% active rate). Mefenamic acid has been previously shown to displace T3 and T4 from plasma binding protein <italic>in vivo</italic> (<xref rid="c46" ref-type="bibr">Koizumi et al. 1984</xref>), from transthyretin isolated from human plasma <italic>in vitro</italic> (<xref rid="c64" ref-type="bibr">Munro et al. 1989</xref>), and from thyroid hormone binding proteins, such as transthyretin and albumin in placental cytosol (<xref rid="c57" ref-type="bibr">McKinnon et al. 2005</xref>). It can be inferred that the molecular shape of mefenamic acid may resemble that of T3 and T4 given that it can displace these ligands from their binding protein sites. Risarestat is a thiazolidinedione aldose reductase inhibitor and diclazuril is a broad-spectrum, anti-coccidial drug with an undefined mechanism of action. Both lacked cytotoxicity in the GH3 viability assay and were modestly to moderately active in other Tox21 cytotoxicity assays, at 12% and 33% active, respectively. Both have an amine-dione structural feature that, in the case of risarestat, is part of the thiazolindinedione group, a known carboxylic acid–mimetic that participates in a critical hydrogen bond in peroxisome proliferator-activated receptor ligands (<xref rid="c22" ref-type="bibr">Falck et al. 2008</xref>). These structural features may be required to provide binding through a mechanism used by the carboxylic acid group of T3/T4 in hydrogen bonding to arginine residues, a key binding determinant for TR (<xref rid="c56" ref-type="bibr">Martínez et al. 2009</xref>). Indeed, Pfizer developed a 6-azauracil structural series highly related to diclazuril as <inline-formula><mml:math id="m209"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> subtype-selective thyromimetics (<xref rid="c20" ref-type="bibr">Dow et al. 2003</xref>). Daunorubicin was also very active in the nuclear translocation assay but was cytotoxic in two-thirds of the cytotoxicity/viability assays in which it was tested. Although positive in the translocation assay, daunorubicin significantly reduced average cell number per field in this high-content imaging assay, suggesting significant cytotoxicity. Thus, we considered it unlikely that the compound was acting directly on TR. Another active compound in the translocation assay that reduced average cell number per field was omacetaxine mepesuccinate, a natural product with chemotherapeutic properties via inhibition of protein translation (<xref rid="c26" ref-type="bibr">Gandhi et al. 2014</xref>). It also had a cytotoxicity <inline-formula><mml:math id="m210"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> twice as high as that of the TR reporter gene in GH3 cells, suggesting that direct action on TR is unlikely. Other compounds, less active in the translocation assay, were C.I. Basic Red 9 monohydrochloride, PP242, Methyl Red, lercanidipine hydrochloride, and ecopipam. These had cytotoxicity potencies less than 2-fold greater than the reporter gene, which may also indicate indirect effects on TR. Thus, only 3 of the top 12 candidate TR antagonists showing concentration-dependent effects on TR translocation appear to be potentially direct TR antagonists. Their structures and those of the other 9 are shown in Figure S3.</p>
      <fig id="f5" orientation="portrait" position="float">
        <label>Figure 5.</label>
        <caption>
          <p>Example characterization of thyroid hormone receptor (TR) antagonists. Candidate TR antagonists were tested in concentration–response format in the TR_GH3 rat pituitary cell line used in the quantitative high-throughput screen (qHTS) concurrent with viability testing using the CellTiter-Glo reagent. (A) Dichlofluanid, an example of an active compound in the TR_Luc_GH3 antagonist mode assay; however, it showed loss of viability at virtually identical concentrations, suggesting the activity is likely due to cytotoxicity. (B) Carfilzomib, a selective proteasome inhibitor, was active in the TR_Luc_GH3 antagonist mode assay while causing loss of viability at slightly higher concentrations. It also showed concentration-dependent stimulation of <inline-formula><mml:math id="m211"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> nuclear translocation and may be an indirect modulator of TR. (C) Risarestat, a thiazolidinedione aldose reductase inhibitor, was active in the TR_Luc_GH3 antagonist mode assay with little loss of viability and showed a concentration-dependent stimulation of <inline-formula><mml:math id="m212"><mml:mrow><mml:mtext>GFP-GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> nuclear translocation and was classified as a likely direct TR antagonist.</p>
        </caption>
        <alt-text>Figure 5A comprises two line graphs plotting percentage activity (n equals 3) ranging from negative 50 to 150 in increments of 50 (y-axis) across log 10 concentration (micromolar) ranging from negative 3 to 2 in unit increments (x-axis), each for TR GH3 and GH3 viability. Figure 5B comprises two line graphs plotting percentage activity (n equals 3) ranging from negative 50 to 150 in increments of 50 (y-axis) across log 10 concentration (micromolar) ranging from negative 3 to 1 in unit increments (x-axis), each for TR GH3 and GH3 viability. Another bar graph plots fold change plus or minus S E M (n equals 3) ranging from 0 to 3 in unit increments (y-axis) across concentration (micromolar) ranging from 0 to 100 (x-axis) for TR MCF7. Figure 5C comprises two line graphs plotting percentage activity (n equals 3) ranging from negative 50 to 150 in increments of 50 (y-axis) across log 10 concentration (micromolar) ranging from negative 3 to 1 in unit increments (x-axis), each for TR GH3 and GH3 viability. Another bar graph plots fold change plus or minus S E M (n equals 3) ranging from 0 to 3 in unit increments (y-axis) across concentration (micromolar) ranging from 0 to 100 (x-axis) for TR MCF7.</alt-text>
        <graphic xlink:href="ehp-127-097009-g0005"/>
      </fig>
      <p>The three highest confidence antagonist compounds were evaluated for similarity to other compounds in the DSSTox list and the Tox21 library as was done with the agonists. There were 204 compounds identified in DSSTox (see Excel Table S10) but none were included in the Tox21 library. Of the 204 compounds, 34 were present on one or more lists included on the CompTox Chemicals Dashboard, and these may be of higher priority for follow-up work. It should be noted that the structure of each one of these three highest confidence antagonists had <inline-formula><mml:math id="m213"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math></inline-formula> Tanimoto similarity to the other two.</p>
      <p>To put our screening results in context with other important endocrine nuclear receptors, we compared our TR screening results with those of estrogen and androgen receptors. A subset of the Tox21 library of approximately 1,600 chemicals were screened in numerous orthogonal assays for estrogen and androgen receptors, somewhat analogous to the follow-up assays performed for TR, and the data used in integrated pathway models predicting receptor activity. The active rate for these 1,600 chemicals for agonist and antagonist modes for estrogen receptor was 4.3% and 0.6%; for androgen receptor was 0.5% and 8.8%; and for TR 0.0% and 0.1%, respectively (see Excel Table S11) (<xref rid="c41" ref-type="bibr">Judson et al. 2015</xref>; <xref rid="c45" ref-type="bibr">Kleinstreuer et al. 2017</xref>).</p>
    </sec>
  </sec>
  <sec id="s4">
    <title>Discussion</title>
    <p>Understanding the interaction of xenobiotics with endocrine nuclear receptors is of critical importance for protecting the health of humans and wildlife. The U.S. EPA’s EDSP was established to provide the means to test pesticides and other environmental chemicals for their potential to interact with the endocrine systems of human and wildlife. Much of this effort was initially focused on screens and models for identifying xenobiotics targeting the estrogen and androgen receptors with numerous chemicals identified that bind and interfere with functions of these receptors (<xref rid="c7" ref-type="bibr">Browne et al. 2015</xref>; <xref rid="c45" ref-type="bibr">Kleinstreuer et al. 2017</xref>). The TR, no less a critical endocrine receptor, has been associated with only a small number of possible chemical modulator classes, such as the PBDEs and PCBs, suggesting a much more restrictive ligand-binding pocket (<xref rid="c58" ref-type="bibr">Meerts et al. 2001</xref>). We tested that hypothesis through a large-scale screen of an extensive collection of environmental chemicals for agonist or antagonist activity in a TR transactivation assay. Only 11 chemicals of 8,305 unique chemical structures were identified as direct TR ligands: 8 were agonists and 3 antagonists, supporting the conclusion that TR is a very restrictive receptor with limited ligand structural diversity.</p>
    <p>Almost all the agonists, particularly the more efficacious agonists, are T3 analogs. Like T3, these compounds were both potent and displayed generally full activation of the receptor. Another class of active compounds was shown to agonize RXR through the TR:RXR heterodimer, resulting in partial agonist activity in the transactivation assays. This activity, called a permissive heterodimer effect, has been previously described (<xref rid="c9" ref-type="bibr">Castillo et al. 2004</xref>). As expected, these compounds were inactive in the coactivator recruitment assay given that no RXR was present. The physiological/toxicological relevance of this effect and whether xenobiotics could affect TR-regulated genes through RXR <italic>in vivo</italic> is unclear due to lack of published studies. Nevertheless, all the high confidence RXR agonists that modulated the TR reporter gene were pharmaceuticals (or naturally occurring substances used as pharmaceuticals). Thus, from the compounds tested, there were no environmental chemicals of potential concern with significant potency acting through this pharmacological mechanism although, as previously mentioned, hydroxylated polybrominated diphenyl ethers (PDBEs) were not part of the chemical library.</p>
    <p>Identification of antagonists using the GH3-TRE-Luc reporter gene assay was much more challenging. Many compounds decreased cell viability at concentrations similar to their activity in the reporter gene assay, supporting the conclusion that the results are false positives with respect to TR antagonism. However, many other compounds, including examples of known cytotoxic and cytostatic ones, showed more potent effects against the reporter gene, which could be interpreted as true TR antagonism. It is important to consider, though, that the end points measured—a decrease in reporter gene activity versus a loss of a constitutive protease activity used for the cell viability measurement—are not necessarily coordinately linked either kinetically or quantitatively. Cytotoxicity mechanisms vary and can have very different kinetics; necrosis versus apoptosis as mechanisms of cell death serves as an example at a high level. Thus, chemicals could demonstrate different ratios of cytotoxic concentrations to the <inline-formula><mml:math id="m214"><mml:mrow><mml:msub><mml:mrow><mml:mtext>AC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> for inhibition of the reporter gene (<xref rid="c77" ref-type="bibr">Riss and Moravec 2004</xref>). An orthogonal assay helped to confirm TR activity using a novel chimeric GR-TR nuclear receptor fused to a GFP that allows functional determination of ligand binding to the receptor through monitoring by automated fluorescent imaging of nuclear translocation/stabilization of the fusion protein. Most of the candidate antagonists were not active in the translocation assay, showing how confounding cytotoxicity or other interference mechanisms could be in reporter assay screens. There were 41 compounds that were scored as active at the highest concentration tested in the nuclear translocation assay and were negative in a background fluorescence counter screen. Of these, 16 produced concentration-dependent effects, increasing confidence in their activity as TR antagonists. The other 25 putative TR antagonists may be considered equivocal or only weakly active at high concentrations, with further testing required to confirm their activity.</p>
    <p>The most active TR antagonists identified were all from the pharmaceutical use class of compounds. Mefenamic acid is an anthranilic acid and nonsteroidal anti-inflammatory drug (NSAID) (<xref rid="c70" ref-type="bibr">Paulus and Whitehouse 1973</xref>) with no reported previous characterization as a modulator of TR. However, it was previously shown to increase plasma T3 and T4 levels following an intravenous injection in rats, reportedly due to displacement of T3 and T4 from plasma binding protein, suggesting a similarity in molecular structure between mefenamic acid and T3 and T4 (<xref rid="c46" ref-type="bibr">Koizumi et al. 1984</xref>). Two drugs identified as TR antagonists in this work without previous evidence of TR activity are risarestat, an aldose reductase inhibitor developed as a treatment for hypoglycemia associated with diabetes, and diclazuril, an anticoccidial used in the poultry industry. The significance of these drugs having potential TR antagonist activity is unknown, but the potencies affecting TR activity are moderately high (ranging from <inline-formula><mml:math id="m215"><mml:mrow><mml:mn>5</mml:mn><mml:mo>–</mml:mo><mml:mn>20</mml:mn><mml:mspace width="0.3em"/><mml:mi mathvariant="normal">μ</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:math></inline-formula>); as such, TR activity may occur at concentrations much higher than the systemic concentrations produced by therapeutic dosages. Nevertheless, this may warrant some investigation to understand whether such activities may be of pathophysiological relevance. Defining specific TR antagonists is challenging due to the potential for multiple mechanisms of TR modulation (i.e., indirect activity) and assay interference from multiple sources, including cytotoxicity. Omacetaxine mepesuccinate is a natural product oncolytic drug with a mechanism of action through inhibition of protein translation (<xref rid="c92" ref-type="bibr">Wetzler and Segal 2011</xref>) and is active nonspecifically in reporter gene assays. Activity of omacetaxine in the nuclear translocation assay could also be rationalized as an indirect effect, such as inhibition of the translation of chaperone proteins required to maintain the GFP-tagged human <inline-formula><mml:math id="m216"><mml:mrow><mml:mtext>GR-TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> hybrid receptor reporter protein in the cytoplasm. Thus, even with multiple characterization assays and manual curation, it is a challenge to identify a specific antagonist mechanism of action.</p>
    <p>The overall conclusion of this large-scale screening of environmental and other chemicals for activity directly against the TR supports the hypothesis that TR is a very selective nuclear receptor. Others have described several notable classes of chemicals as TR modulators that were not reported here. Bisphenol A and brominated analogs have been characterized as TR antagonists (<xref rid="c44" ref-type="bibr">Kitamura et al. 2002</xref>; <xref rid="c62" ref-type="bibr">Moriyama et al. 2002</xref>). We found BPA (and BPA analogs) active in suppressing the TR transactivation assay; however, their activities were concurrent with cytotoxicity, suggesting that the observed effect on TR could be secondary to cytotoxicity. We have previously measured extensive BPA cytotoxicity and stress responses in the same concentration range and interpret these results as an indication of extensive cell stress, which can be manifested as promiscuous responses with <italic>in vitro</italic> assays (see Figure S4) (<xref rid="c40" ref-type="bibr">Judson et al. 2016</xref>). Likewise, the cardiac anti-arrhythmic amiodarone has been described as a TR antagonist but we, like others, found it cytotoxic at the concentrations at which it inhibits TR (<xref rid="c91" ref-type="bibr">Webb et al. 2002</xref>). Another class of compounds previously characterized as TR modulators are the PCBs and hydryoxylated PDBEs (<xref rid="c39" ref-type="bibr">Iwasaki et al. 2002</xref>; <xref rid="c47" ref-type="bibr">Kojima et al. 2009</xref>; <xref rid="c59" ref-type="bibr">Meerts et al. 2000</xref>; <xref rid="c95" ref-type="bibr">Zhou et al. 2002</xref>). None of the previously identified specific compounds were in the screening library, although four nonhydroxylated PCBs were included but were inactive against TR. In general, the physicochemical properties of PCBs are inconsistent with adequate aqueous solubility for <italic>in vitro</italic> testing, in particular for the nonhydroxylated compounds having high partition coefficient, whereas the hydroxylated analogs have limited commercial availability and high costs to procure.</p>
    <p>Structural features of the TR suggest that the receptor may be restricted in the breadth of potential ligands recognized. Wagner et al. (<xref rid="c86" ref-type="bibr">1995</xref>) noted early on in studying the TR that the ligand–receptor interaction is very tight and that the ligand (i.e., T3) is completely buried in the ligand-binding pocket upon ligand-induced helix 12 conformational change. Subsequent attempts to develop TR agonists have relied upon a general design strategy based in solved crystal structures, yielding a pharmacophore model consisting of an acidic head group participating in a number of strong polar interactions with basic amino acid residues at one end of the binding pocket, a middle section characterized almost exclusively by hydrophobic interactions with the hydrophobic amino acids lining most of the pocket and including residues from helix 12, and a tail section with hydrogen bonding capability illustrated by the 4ʹ hydroxyl and 3ʹ steric iodine in the distal ring of T3 (<xref rid="c85" ref-type="bibr">Valadares et al. 2009</xref>). Selectivity between <inline-formula><mml:math id="m217"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m218"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> is difficult to achieve because there is only a single amino acid difference in the ligand-binding pocket (<xref rid="c37" ref-type="bibr">Huang et al. 2010</xref>). Specifically designed antagonists include protrusions from the mid-section that block helix 12 from obtaining a conformation that permits coactivator binding based on the extension hypothesis for nuclear receptor antagonists (<xref rid="c75" ref-type="bibr">Ribeiro et al. 1998</xref>; <xref rid="c91" ref-type="bibr">Webb et al. 2002</xref>). We note that our high confidence agonists and antagonists all meet most of these features. They contain either a carboxylic acid head group or a functionally similar structure capable of hydrogen bonding such as a thiazolidinedione or dioxytriazine. All have hydrophobic mid-sections. Note that although the endogenous ligands contain multiple iodines in this region involved in hydrophobic interactions and a halogen bond(s), their hydrophobicity can be replaced with methyl or dimethyl groups as in the potent agonist GC-1, which lacks iodine (<xref rid="c12" ref-type="bibr">Chiellini et al. 1998</xref>). It is interesting that in the major classes of nonpharmaceuticals previously reported as agonists or antagonists outside of this study (e.g., the PBDEs, PCBs, and bisphenols), the molecules lack an acidic head group. Given the promiscuity of at least some of these molecules, for example, tetrabromobisphenol A, it may suggest the carboxylate head group is critical for generating selectivity for TR. The novel candidate agonist betamipron contains a carboxylate head group but lacks an extensive hydrophobic middle, which likely contributes to its weak affinity. With respect to antagonists, the diclazuril structure contains a dioxytriazine head group likely participating in hydrogen bonding, a tri-halogenated biphenyl structure analogous to T3, and a nitrile group extension in the hydrophobic region. Although not necessarily considered a large protrusion as found in other nuclear receptor antagonists, it is a very polar group that possibly could destabilize hydrophobic helix 12 binding. We evaluated the structure using the similarity ensemble approach (SEA), which identifies putative small molecule targets through the structural similarity of a query structure to target ligands and found <inline-formula><mml:math id="m219"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m220"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> to be the top two matches with <inline-formula><mml:math id="m221"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>1.98</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>–</mml:mo><mml:mn>20</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="m222"><mml:mrow><mml:mn>7.1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>–</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, respectively (<ext-link ext-link-type="uri" xlink:href="http://sea.bkslab.org/">http://sea.bkslab.org/</ext-link>) (<xref rid="c43" ref-type="bibr">Keiser et al. 2007</xref>). Risarestat also mapped to <inline-formula><mml:math id="m223"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">α</mml:mi></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="m224"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>9.99</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>–</mml:mo><mml:mn>16</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>) and <inline-formula><mml:math id="m225"><mml:mrow><mml:mtext>TR</mml:mtext><mml:mi mathvariant="normal">β</mml:mi></mml:mrow></mml:math></inline-formula> (<inline-formula><mml:math id="m226"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>1.2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>–</mml:mo><mml:mn>12</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>) using SEA. Most of the other candidate TR antagonists bear little resemblance to the T3 structure and are unlikely to directly bind to the LBD. They could, however, bind to the coactivator site to prevent agonist activity or work more indirectly, as previously mentioned, through mechanisms such as proteasome inhibition.</p>
    <p>Although neurodevelopmental and other toxicities are of high concern for chemicals affecting the thyroid axis (<xref rid="c10" ref-type="bibr">Chen et al. 2016</xref>), it is likely that the molecular-initiating events that result in disruption of the thyroid axis occur through pathways beyond their direct effects on the TR. In contrast to the estrogen and androgen steroid hormone receptors, each affected by numerous environmental chemicals in the agonist or antagonist mode, respectively, TR behaves as a much more selective nuclear receptor for both agonist and antagonist modes of action. Indeed, we compared, for 1,600 chemicals, the chemical hit rate for estrogen and androgen receptors (0.5–8.8%, depending on receptor and mode) versus the more limited active rate for TR (0–0.1%, depending on mode) using the system of assays described herein; this suggested that even with the same chemical set, TR will be expected to be active at a lower rate than more permissive endocrine receptors. However, numerous mechanisms that alter levels of the endogenous hormones T3 and T4 may result in indirect effects, ultimately mediated through changed TR signaling levels and consequently pathological outcomes (<xref rid="c65" ref-type="bibr">Murk et al. 2013</xref>). Screening for disruptors of thyroid hormone function, regardless of mechanism, is critically important because maternal hypothyroxinemia correlates with irreversible neonatal cognitive and functional brain abnormalities (<xref rid="c2" ref-type="bibr">Barone et al. 2000</xref>; <xref rid="c3" ref-type="bibr">Berbel et al. 2009</xref>; <xref rid="c17" ref-type="bibr">Cuevas et al. 2005</xref>; <xref rid="c35" ref-type="bibr">Howdeshell 2002</xref>; <xref rid="c63" ref-type="bibr">Morreale de Escobar et al. 2000</xref>; <xref rid="c76" ref-type="bibr">Rice and Barone 2000</xref>; <xref rid="c97" ref-type="bibr">Zoeller and Crofton 2000</xref>), with decrements in intelligence quotient, cognition, socialization, and motor function following decreased maternal T4 (<xref rid="c31" ref-type="bibr">Haddow et al. 1999</xref>; <xref rid="c3" ref-type="bibr">Berbel et al. 2009</xref>; <xref rid="c49" ref-type="bibr">Kooistra et al. 2006</xref>; <xref rid="c53" ref-type="bibr">Li et al. 2010</xref>; <xref rid="c72" ref-type="bibr">Pop et al. 1999</xref>, <xref rid="c71" ref-type="bibr">2003</xref>). Although transient disruption of thyroid hormone supply during neurodevelopment manifests in permanent alterations, the effects of thyroid hormone disruption in adults are generally reversible and treated pharmacologically (<xref rid="c6" ref-type="bibr">Biondi and Wartofsky 2014</xref>; <xref rid="c60" ref-type="bibr">Miller et al. 2009</xref>). It is well documented that T3 activates TRs to transcriptionally regulate gene expression required for myelination and neuronal and glial cell differentiation and migration in the developing brain during pregnancy and the early postnatal period (<xref rid="c5" ref-type="bibr">Bernal 2007</xref>; <xref rid="c15" ref-type="bibr">Clairman et al. 2015</xref>). Postnatally, neuronal cell migration in the hippocampus and cerebellum along with glial cell development and myelination also requires normal neonatal thyroid function (<xref rid="c73" ref-type="bibr">Porterfield and Hendrich 1993</xref>; <xref rid="c74" ref-type="bibr">Quignodon et al. 2004</xref>; <xref rid="c93" ref-type="bibr">Williams 2008</xref>). For example, experimentally induced hypo- and hyperthyroidism results in an altered external granular layer development in the rat cerebellar cortex at 10 d of age, probably through effects on the cell cycle (<xref rid="c51" ref-type="bibr">Lauder 1977</xref>) and, further, radiothyroidectomy of newborn rat pups resulted in failure of myelination of brain white matter (<xref rid="c78" ref-type="bibr">Rosman et al. 1972</xref>). More recent work in rats has demonstrated that hippocampal neurogenesis is reduced by developmental thyroid hormone disruption and that heterotopias are induced by chemically induced hypothyroidism (<xref rid="c27" ref-type="bibr">Gilbert et al. 2017</xref>; <xref rid="c67" ref-type="bibr">O’Shaughnessy et al. 2018</xref>). The clear connection between developmental thyroid hormone disruption and neurotoxicity underscores the need for a screening strategy to identify potential thyroid axis disrupting chemicals.</p>
    <p>Because of its broad and critical importance, resources are being applied to better understand the major mechanisms and targets of environmental chemicals that may impact growth and development mediated by the thyroid axis beyond direct effects on the thyroid hormone receptors. Efforts in the U.S. EPA’s ToxCast program have been initiated, including targeting and screening for inhibition of thyroperoxidase and thyroid uptake of iodide via the sodium-iodide symporter, both involved in thyroid hormone biosynthesis; inhibition of the MCT8 transmembrane transporter, which permits cellular uptake of thyroid hormones; and inhibition of human deiodinase type 1 (DIO1) and type 2 (DIO2) enzymes, which help maintain thyroid hormone homeostasis (<xref rid="c19" ref-type="bibr">Dong and Wade 2017</xref>; <xref rid="c34" ref-type="bibr">Hornung et al. 2018</xref>; <xref rid="c69" ref-type="bibr">Paul Friedman et al. 2016</xref>; <xref rid="c88" ref-type="bibr">Wang et al. 2018</xref>). Ongoing efforts in this area are needed to elucidate the molecular-initiating events of most relevance to thyroid hormone disruption by environmental exposures and, subsequently, to combine data from multiple molecular-initiating events for thyroid hormone disruption into outputs for screening-level chemical safety evaluation.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data">
      <media xlink:href="ehp-127-097009-s003.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <media xlink:href="ehp-127-097009-s001.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <media xlink:href="ehp-127-097009-s002.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p>We thank N. Miller and S. Michael for the technical assistance with the thyroid hormone receptor primary screening and A. Murk for use of the GH3-TRE-Luc cell line. We are grateful to T. Stoker, J. Olker, and M. Gwinn for critical reviews of the manuscript. This work was supported by the U.S. Environmental Protection Agency [Interagency Agreement (IAA) Y3-HG-7026-03], the National Center for Advancing Translational Sciences (NCATS) Intramural Research Program, and the National Institute of Environmental Health Sciences/Division of the National Toxicology Program to the NCATS, National Institutes of Health (IAA NTR 12003).</p>
  </ack>
  <fn-group>
    <fn fn-type="other" specific-use="pdf-only">
      <p>Supplemental Material is available online (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1289/EHP5314">https://doi.org/10.1289/EHP5314</ext-link>).</p>
    </fn>
    <fn fn-type="other">
      <p>The views expressed in this paper are those of the authors and do not necessarily reflect the statements, opinions, views, conclusions, or policies of the U.S. Environmental Protection Agency; the National Center for Advancing Translational Sciences, National Institutes of Health; or the U.S. Food and Drug Administration. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.</p>
    </fn>
    <fn fn-type="financial-disclosure">
      <p>The authors declare they have no actual or potential competing financial interests.</p>
    </fn>
    <fn specific-use="pdf-only" fn-type="other">
      <p><bold>Note to readers with disabilities:</bold><italic>EHP</italic> strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in <italic>EHP</italic> articles may not conform to <ext-link ext-link-type="uri" xlink:href="http://ehp.niehs.nih.gov/accessibility/">508 standards</ext-link> due to the complexity of the information being presented. If you need assistance accessing journal content, please contact <email>ehponline@niehs.nih.gov</email>. Our staff will work with you to assess and meet your accessibility needs within 3 working days.</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>References</title>
    <ref id="c1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araki</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Ying</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Furuya</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>SY</given-names></name></person-group><year>2005</year>. <article-title>Thyroid hormone receptor β mutants: dominant negative regulators of peroxisome proliferator-activated receptor γ action</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>102</volume>(<issue>45</issue>):<fpage>16251</fpage>–<lpage>16256</lpage>, PMID: 16260719, <pub-id pub-id-type="doi">10.1073/pnas.0508556102</pub-id>.<?supplied-pmid 16260719?><pub-id pub-id-type="pmid">16260719</pub-id></mixed-citation>
    </ref>
    <ref id="c2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barone</surname><given-names>S</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Das</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Lassiter</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>White</surname><given-names>LD</given-names></name></person-group><year>2000</year>. <article-title>Vulnerable processes of nervous system development: a review of markers and methods</article-title>. <source>Neurotoxicology</source><volume>21</volume>(<issue>1–2</issue>):<fpage>15</fpage>–<lpage>36</lpage>, PMID: 10794382.<?supplied-pmid 10794382?><pub-id pub-id-type="pmid">10794382</pub-id></mixed-citation>
    </ref>
    <ref id="c3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berbel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mestre</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Santamaria</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Palazón</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Franco</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Graells</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group><year>2009</year>. <article-title>Delayed neurobehavioral development in children born to pregnant women with mild hypothyroxinemia during the first month of gestation: the importance of early iodine supplementation</article-title>. <source>Thyroid</source><volume>19</volume>(<issue>5</issue>):<fpage>511</fpage>–<lpage>519</lpage>, PMID: 19348584, <pub-id pub-id-type="doi">10.1089/thy.2008.0341</pub-id>.<?supplied-pmid 19348584?><pub-id pub-id-type="pmid">19348584</pub-id></mixed-citation>
    </ref>
    <ref id="c4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berkenstam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kristensen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mellström</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Carlsson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Malm</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rehnmark</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><year>2008</year>. <article-title>The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>105</volume>(<issue>2</issue>):<fpage>663</fpage>–<lpage>667</lpage>, PMID: 18160532, <pub-id pub-id-type="doi">10.1073/pnas.0705286104</pub-id>.<?supplied-pmid 18160532?><pub-id pub-id-type="pmid">18160532</pub-id></mixed-citation>
    </ref>
    <ref id="c5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernal</surname><given-names>J</given-names></name></person-group><year>2007</year>. <article-title>Thyroid hormone receptors in brain development and function</article-title>. <source>Nat Clin Pract Endocrinol Metab</source><volume>3</volume>(<issue>3</issue>):<fpage>249</fpage>–<lpage>259</lpage>, PMID: 17315033, <pub-id pub-id-type="doi">10.1038/ncpendmet0424</pub-id>.<?supplied-pmid 17315033?><pub-id pub-id-type="pmid">17315033</pub-id></mixed-citation>
    </ref>
    <ref id="c6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biondi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wartofsky</surname><given-names>L</given-names></name></person-group><year>2014</year>. <article-title>Treatment with thyroid hormone</article-title>. <source>Endocr Rev</source><volume>35</volume>(<issue>3</issue>):<fpage>433</fpage>–<lpage>512</lpage>, PMID: 24433025, <pub-id pub-id-type="doi">10.1210/er.2013-1083</pub-id>.<?supplied-pmid 24433025?><pub-id pub-id-type="pmid">24433025</pub-id></mixed-citation>
    </ref>
    <ref id="c7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Judson</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Casey</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Kleinstreuer</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>RS</given-names></name></person-group><year>2015</year>. <article-title>Screening chemicals for estrogen receptor bioactivity using a computational model</article-title>. <source>Environ Sci Technol</source><volume>49</volume>(<issue>14</issue>):<fpage>8804</fpage>–<lpage>8814</lpage>, PMID: 26066997, <pub-id pub-id-type="doi">10.1021/acs.est.5b02641</pub-id>.<?supplied-pmid 26066997?><pub-id pub-id-type="pmid">26066997</pub-id></mixed-citation>
    </ref>
    <ref id="c8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burris</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Solt</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Crumbley</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Griffett</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group><year>2013</year>. <article-title>Nuclear receptors and their selective pharmacologic modulators</article-title>. <source>Pharmacol Rev</source><volume>65</volume>(<issue>2</issue>):<fpage>710</fpage>–<lpage>778</lpage>, PMID: 23457206, <pub-id pub-id-type="doi">10.1124/pr.112.006833</pub-id>.<?supplied-pmid 23457206?><pub-id pub-id-type="pmid">23457206</pub-id></mixed-citation>
    </ref>
    <ref id="c9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castillo</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Sánchez-Martinez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Martínez-Iglesias</surname><given-names>OA</given-names></name>, <name name-style="western"><surname>Palacios</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Aranda</surname><given-names>A</given-names></name></person-group><year>2004</year>. <article-title>A permissive retinoid X receptor/thyroid hormone receptor heterodimer allows stimulation of prolactin gene transcription by thyroid hormone and 9-<italic>cis</italic>-retinoic acid</article-title>. <source>Mol Cell Biol</source><volume>24</volume>(<issue>2</issue>):<fpage>502</fpage>–<lpage>513</lpage>, PMID: 14701725, <pub-id pub-id-type="doi">10.1128/MCB.24.2.502-513.2004</pub-id>.<?supplied-pmid 14701725?><pub-id pub-id-type="pmid">14701725</pub-id></mixed-citation>
    </ref>
    <ref id="c10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Giesy</surname><given-names>JP</given-names></name></person-group><year>2016</year>. <article-title>Identification of thyroid hormone disruptors among Ho-PBDEs: <italic>in vitro</italic> investigations and coregulator involved simulations</article-title>. <source>Environ Sci Technol</source><volume>50</volume>(<issue>22</issue>):<fpage>12429</fpage>–<lpage>12438</lpage>, PMID: 27737548, <pub-id pub-id-type="doi">10.1021/acs.est.6b02029</pub-id>.<?supplied-pmid 27737548?><pub-id pub-id-type="pmid">27737548</pub-id></mixed-citation>
    </ref>
    <ref id="c11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>PJ</given-names></name></person-group><year>2010</year>. <article-title>Molecular aspects of thyroid hormone actions</article-title>. <source>Endocr Rev</source><volume>31</volume>(<issue>2</issue>):<fpage>139</fpage>–<lpage>170</lpage>, PMID: 20051527, <pub-id pub-id-type="doi">10.1210/er.2009-0007</pub-id>.<?supplied-pmid 20051527?><pub-id pub-id-type="pmid">20051527</pub-id></mixed-citation>
    </ref>
    <ref id="c12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiellini</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Apriletti</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Yoshihara</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Scanlan</surname><given-names>TS</given-names></name></person-group><year>1998</year>. <article-title>A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor</article-title>. <source>Chem Biol</source><volume>5</volume>(<issue>6</issue>):<fpage>299</fpage>–<lpage>306</lpage>, PMID: 9653548, <pub-id pub-id-type="doi">10.1016/S1074-5521(98)90168-5</pub-id>.<?supplied-pmid 9653548?><pub-id pub-id-type="pmid">9653548</pub-id></mixed-citation>
    </ref>
    <ref id="c13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiellini</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Apriletti</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Scanlan</surname><given-names>TS</given-names></name></person-group><year>2002</year>. <article-title>Synthesis and biological activity of novel thyroid hormone analogues: 5ʹ-aryl substituted GC-1 derivatives</article-title>. <source>Bioorg Med Chem</source><volume>10</volume>(<issue>2</issue>):<fpage>333</fpage>–<lpage>346</lpage>, PMID: 11741782, <pub-id pub-id-type="doi">10.1016/s0968-0896(01)00284-x</pub-id>.<?supplied-pmid 11741782?><pub-id pub-id-type="pmid">11741782</pub-id></mixed-citation>
    </ref>
    <ref id="c14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cioffi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gentile</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Silvestri</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Goglia</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Lombardi</surname><given-names>A</given-names></name></person-group><year>2018</year>. <article-title>Effect of iodothyronines on thermogenesis: focus on brown adipose tissue</article-title>. <source>Front Endocrinol (Lausanne)</source><volume>9</volume>:<fpage>254</fpage>, PMID: 29875734, <pub-id pub-id-type="doi">10.3389/fendo.2018.00254</pub-id>.<?supplied-pmid 29875734?><pub-id pub-id-type="pmid">29875734</pub-id></mixed-citation>
    </ref>
    <ref id="c15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clairman</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Skocic</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lischinsky</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Rovet</surname><given-names>J</given-names></name></person-group><year>2015</year>. <article-title>Do children with congenital hypothyroidism exhibit abnormal cortical morphology?</article-title><source>Pediatr Res</source><volume>78</volume>(<issue>3</issue>):<fpage>286</fpage>–<lpage>297</lpage>, PMID: 25978801, <pub-id pub-id-type="doi">10.1038/pr.2015.93</pub-id>.<?supplied-pmid 25978801?><pub-id pub-id-type="pmid">25978801</pub-id></mixed-citation>
    </ref>
    <ref id="c16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crisman</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>CN</given-names></name>, <name name-style="western"><surname>Jenkins</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Scheiber</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thoma</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>ZB</given-names></name>, <etal>et al.</etal></person-group><year>2007</year>. <article-title>Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data</article-title>. <source>J Chem Inf Model</source><volume>47</volume>(<issue>4</issue>):<fpage>1319</fpage>–<lpage>1327</lpage>, PMID: 17608469, <pub-id pub-id-type="doi">10.1021/ci6005504</pub-id>.<?supplied-pmid 17608469?><pub-id pub-id-type="pmid">17608469</pub-id></mixed-citation>
    </ref>
    <ref id="c17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuevas</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ausó</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Telefont</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Morreale de Escobar</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sotelo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Berbel</surname><given-names>P</given-names></name></person-group><year>2005</year>. <article-title>Transient maternal hypothyroxinemia at onset of corticogenesis alters tangential migration of medial ganglionic eminence-derived neurons</article-title>. <source>Eur J Neurosci</source><volume>22</volume>(<issue>3</issue>):<fpage>541</fpage>–<lpage>551</lpage>, PMID: 16101736, <pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04243.x</pub-id>.<?supplied-pmid 16101736?><pub-id pub-id-type="pmid">16101736</pub-id></mixed-citation>
    </ref>
    <ref id="c18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeVito</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Biegel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Brouwer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Brucker-Davis</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cheek</surname><given-names>AO</given-names></name>, <etal>et al.</etal></person-group><year>1999</year>. <article-title>Screening methods for thyroid hormone disruptors</article-title>. <source>Environ Health Perspect</source><volume>107</volume>(<issue>5</issue>):<fpage>407</fpage>–<lpage>415</lpage>, PMID: 10210697, <pub-id pub-id-type="doi">10.1289/ehp.99107407</pub-id>.<?supplied-pmid 10210697?><pub-id pub-id-type="pmid">10210697</pub-id></mixed-citation>
    </ref>
    <ref id="c19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wade</surname><given-names>MG</given-names></name></person-group><year>2017</year>. <article-title>Application of a nonradioactive assay for high throughput screening for inhibition of thyroid hormone uptake via the transmembrane transporter MCT8</article-title>. <source>Toxicol In Vitro</source><volume>40</volume>:<fpage>234</fpage>–<lpage>242</lpage>, PMID: 28119167, <pub-id pub-id-type="doi">10.1016/j.tiv.2017.01.014</pub-id>.<?supplied-pmid 28119167?><pub-id pub-id-type="pmid">28119167</pub-id></mixed-citation>
    </ref>
    <ref id="c20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dow</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Paight</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Hank</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Chiang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cornelius</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group><year>2003</year>. <article-title>Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics</article-title>. <source>Bioorg Med Chem Lett</source><volume>13</volume>(<issue>3</issue>):<fpage>379</fpage>–<lpage>382</lpage>, PMID: 12565933, <pub-id pub-id-type="doi">10.1016/S0960-894X(02)00947-2</pub-id>.<?supplied-pmid 12565933?><pub-id pub-id-type="pmid">12565933</pub-id></mixed-citation>
    </ref>
    <ref id="c21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duncan Bassett</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>GR</given-names></name></person-group><year>2018</year>. <article-title>Analysis of physiological responses to thyroid hormones and their receptors in bone</article-title>. <source>Methods Mol Biol</source><volume>1801</volume>:<fpage>123</fpage>–<lpage>154</lpage>, PMID: 29892822, <pub-id pub-id-type="doi">10.1007/978-1-4939-7902-8_12</pub-id>.<?supplied-pmid 29892822?><pub-id pub-id-type="pmid">29892822</pub-id></mixed-citation>
    </ref>
    <ref id="c22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falck</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Koduru</surname><given-names>SR</given-names></name></person-group><year>2008</year>. <article-title>Electrophilic α-thiocyanation of chiral and achiral <italic>N</italic>-acyl imides. A convenient route to 5-substituted and 5,5-disubstituted 2,4-thiazolidinediones</article-title>. <source>Bioorg Med Chem Lett</source><volume>18</volume>(<issue>6</issue>):<fpage>1768</fpage>–<lpage>1771</lpage>, PMID: 18308568, <pub-id pub-id-type="doi">10.1016/j.bmcl.2008.02.034</pub-id>.<?supplied-pmid 18308568?><pub-id pub-id-type="pmid">18308568</pub-id></mixed-citation>
    </ref>
    <ref id="c23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filer</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Kothiya</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Setzer</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Judson</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>MT</given-names></name></person-group><year>2017</year>. <article-title>tcpl: the ToxCast pipeline for high-throughput screening data</article-title>. <source>Bioinformatics</source><volume>33</volume>(<issue>4</issue>):<fpage>618</fpage>–<lpage>620</lpage>, PMID: 27797781, <pub-id pub-id-type="doi">10.1093/bioinformatics/btw680</pub-id>.<?supplied-pmid 27797781?><pub-id pub-id-type="pmid">27797781</pub-id></mixed-citation>
    </ref>
    <ref id="c24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freitas</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cano</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Craig-Veit</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Goodson</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Furlow</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Murk</surname><given-names>AJ</given-names></name></person-group><year>2011</year>. <article-title>Detection of thyroid hormone receptor disruptors by a novel stable <italic>in vitro</italic> reporter gene assay</article-title>. <source>Toxicol In Vitro</source><volume>25</volume>(<issue>1</issue>):<fpage>257</fpage>–<lpage>266</lpage>, PMID: 20732405, <pub-id pub-id-type="doi">10.1016/j.tiv.2010.08.013</pub-id>.<?supplied-pmid 20732405?><pub-id pub-id-type="pmid">20732405</pub-id></mixed-citation>
    </ref>
    <ref id="c25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freitas</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mengeling</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Houck</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group><year>2014</year>. <article-title>Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform</article-title>. <source>Curr Chem Genom Transl Med</source><volume>8</volume>:<fpage>36</fpage>–<lpage>46</lpage>, PMID: 24772387, <pub-id pub-id-type="doi">10.2174/2213988501408010036</pub-id>.<?supplied-pmid 24772387?><pub-id pub-id-type="pmid">24772387</pub-id></mixed-citation>
    </ref>
    <ref id="c26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Plunkett</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Cortes</surname><given-names>JE</given-names></name></person-group><year>2014</year>. <article-title>Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia</article-title>. <source>Clin Cancer Res</source><volume>20</volume>(<issue>7</issue>):<fpage>1735</fpage>–<lpage>1740</lpage>, PMID: 24501394, <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1283</pub-id>.<?supplied-pmid 24501394?><pub-id pub-id-type="pmid">24501394</pub-id></mixed-citation>
    </ref>
    <ref id="c27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Gomez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Johnstone</surname><given-names>AFM</given-names></name>, <name name-style="western"><surname>Ramos</surname><given-names>RL</given-names></name></person-group><year>2017</year>. <article-title>Adult hippocampal neurogenesis is impaired by transient and moderate developmental thyroid hormone disruption</article-title>. <source>Neurotoxicology</source><volume>59</volume>:<fpage>9</fpage>–<lpage>21</lpage>, PMID: 28048979, <pub-id pub-id-type="doi">10.1016/j.neuro.2016.12.009</pub-id>.<?supplied-pmid 28048979?><pub-id pub-id-type="pmid">28048979</pub-id></mixed-citation>
    </ref>
    <ref id="c28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Rovet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Koibuchi</surname><given-names>N</given-names></name></person-group><year>2012</year>. <article-title>Developmental thyroid hormone disruption: prevalence, environmental contaminants and neurodevelopmental consequences</article-title>. <source>Neurotoxicology</source><volume>33</volume>(<issue>4</issue>):<fpage>842</fpage>–<lpage>852</lpage>, PMID: 22138353, <pub-id pub-id-type="doi">10.1016/j.neuro.2011.11.005</pub-id>.<?supplied-pmid 22138353?><pub-id pub-id-type="pmid">22138353</pub-id></mixed-citation>
    </ref>
    <ref id="c29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Govindan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Denis</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Webb</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Walfish</surname><given-names>PG</given-names></name></person-group><year>2009</year>. <article-title>Identification of CCR4 and other essential thyroid hormone receptor co-activators by modified yeast synthetic genetic array analysis</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>106</volume>(<issue>47</issue>):<fpage>19854</fpage>–<lpage>19859</lpage>, PMID: 19903885, <pub-id pub-id-type="doi">10.1073/pnas.0910134106</pub-id>.<?supplied-pmid 19903885?><pub-id pub-id-type="pmid">19903885</pub-id></mixed-citation>
    </ref>
    <ref id="c30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grijota-Martínez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Samarut</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Scanlan</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Morte</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bernal</surname><given-names>J</given-names></name></person-group><year>2011</year>. <article-title><italic>In vivo</italic> activity of the thyroid hormone receptor β- and α-selective agonists GC-24 and CO23 on rat liver, heart, and brain</article-title>. <source>Endocrinology</source>, PMID: 21239431, <pub-id pub-id-type="doi">10.1210/en.2010-0813</pub-id>.<?supplied-pmid 21239431?><pub-id pub-id-type="pmid">21239431</pub-id></mixed-citation>
    </ref>
    <ref id="c31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddow</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Palomaki</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Allan</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Knight</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Gagnon</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group><year>1999</year>. <article-title>Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child</article-title>. <source>N Engl J Med</source><volume>341</volume>(<issue>8</issue>):<fpage>549</fpage>–<lpage>555</lpage>, PMID: 10451459, <pub-id pub-id-type="doi">10.1056/NEJM199908193410801</pub-id>.<?supplied-pmid 10451459?><pub-id pub-id-type="pmid">10451459</pub-id></mixed-citation>
    </ref>
    <ref id="c32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirouchi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Naganuma</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kawahara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Okada</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kamiya</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Inui</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group><year>1994</year>. <article-title>Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex</article-title>. <source>Jpn J Pharmacol</source><volume>66</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>6</lpage>, PMID: 7861655, <pub-id pub-id-type="doi">10.1254/jjp.66.1</pub-id>.<?supplied-pmid 7861655?><pub-id pub-id-type="pmid">7861655</pub-id></mixed-citation>
    </ref>
    <ref id="c33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Schomburg</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Köhrle</surname><given-names>J</given-names></name></person-group><year>2009</year>. <article-title>Interference of endocrine disrupters with thyroid hormone receptor-dependent transactivation</article-title>. <source>Toxicol Sci</source><volume>110</volume>(<issue>1</issue>):<fpage>125</fpage>–<lpage>137</lpage>, PMID: 19403856, <pub-id pub-id-type="doi">10.1093/toxsci/kfp086</pub-id>.<?supplied-pmid 19403856?><pub-id pub-id-type="pmid">19403856</pub-id></mixed-citation>
    </ref>
    <ref id="c34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hornung</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Korte</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Olker</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Denny</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Knutsen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hartig</surname><given-names>PC</given-names></name>, <etal>et al.</etal></person-group><year>2018</year>. <article-title>Screening the ToxCast phase 1 chemical library for inhibition of deiodinase type 1 activity</article-title>. <source>Toxicol Sci</source><volume>162</volume>(<issue>2</issue>):<fpage>570</fpage>–<lpage>581</lpage>, PMID: 29228274, <pub-id pub-id-type="doi">10.1093/toxsci/kfx279</pub-id>.<?supplied-pmid 29228274?><pub-id pub-id-type="pmid">29228274</pub-id></mixed-citation>
    </ref>
    <ref id="c35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howdeshell</surname><given-names>KL</given-names></name></person-group><year>2002</year>. <article-title>A model of the development of the brain as a construct of the thyroid system</article-title>. <source>Environ Health Perspect</source><volume>110</volume>(<issue>Suppl 3</issue>):<fpage>337</fpage>–<lpage>348</lpage>, PMID: 12060827, <pub-id pub-id-type="doi">10.1289/ehp.02110s3337</pub-id>.<?supplied-pmid 12060827?><pub-id pub-id-type="pmid">12060827</pub-id></mixed-citation>
    </ref>
    <ref id="c36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Htun</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Barsony</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Renyi</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Gould</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Hager</surname><given-names>GL</given-names></name></person-group><year>1996</year>. <article-title>Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>93</volume>(<issue>10</issue>):<fpage>4845</fpage>–<lpage>4850</lpage>, PMID: 8643491, <pub-id pub-id-type="doi">10.1073/pnas.93.10.4845</pub-id>.<?supplied-pmid 8643491?><pub-id pub-id-type="pmid">8643491</pub-id></mixed-citation>
    </ref>
    <ref id="c37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Chandra</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rastinejad</surname><given-names>F</given-names></name></person-group><year>2010</year>. <article-title>Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics</article-title>. <source>Annu Rev Physiol</source><volume>72</volume>:<fpage>247</fpage>–<lpage>272</lpage>, PMID: 20148675, <pub-id pub-id-type="doi">10.1146/annurev-physiol-021909-135917</pub-id>.<?supplied-pmid 20148675?><pub-id pub-id-type="pmid">20148675</pub-id></mixed-citation>
    </ref>
    <ref id="c38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibhazehiebo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Iwasaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Okano-Uchida</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shimokawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ishizaki</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Koibuchi</surname><given-names>N</given-names></name></person-group><year>2011</year>. <article-title>Suppression of thyroid hormone receptor-mediated transcription and disruption of thyroid hormone-induced cerebellar morphogenesis by the polybrominated biphenyl mixture, BP-6</article-title>. <source>Neurotoxicology</source><volume>32</volume>(<issue>4</issue>):<fpage>400</fpage>–<lpage>409</lpage>, PMID: 21396401, <pub-id pub-id-type="doi">10.1016/j.neuro.2011.02.008</pub-id>.<?supplied-pmid 21396401?><pub-id pub-id-type="pmid">21396401</pub-id></mixed-citation>
    </ref>
    <ref id="c39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miyazaki</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Takeshita</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kuroda</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Koibuchi</surname><given-names>N</given-names></name></person-group><year>2002</year>. <article-title>Polychlorinated biphenyls suppress thyroid hormone-induced transactivation</article-title>. <source>Bioch Biophys Res Commun</source><volume>299</volume>(<issue>3</issue>):<fpage>384</fpage>–<lpage>388</lpage>, PMID: 12445811, <pub-id pub-id-type="doi">10.1016/S0006-291X(02)02659-1</pub-id>.<?supplied-pmid 12445811?><pub-id pub-id-type="pmid">12445811</pub-id></mixed-citation>
    </ref>
    <ref id="c40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Judson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Houck</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Richard</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Knudsen</surname><given-names>TB</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>I</given-names></name>, <etal>et al.</etal></person-group><year>2016</year>. <article-title>Analysis of the effects of cell stress and cytotoxicity on <italic>in vitro</italic> assay activity across a diverse chemical and assay space</article-title>. <source>Toxicol Sci</source><volume>153</volume>(<issue>2</issue>):<fpage>409</fpage>, PMID: 27605417, <pub-id pub-id-type="doi">10.1093/toxsci/kfw148</pub-id>.<?supplied-pmid 27605417?><pub-id pub-id-type="pmid">27605417</pub-id></mixed-citation>
    </ref>
    <ref id="c41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Judson</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Magpantay</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Chickarmane</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Haskell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tania</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group><year>2015</year>. <article-title>Integrated model of chemical perturbations of a biological pathway using 18 <italic>in vitro</italic> high-throughput screening assays for the estrogen receptor</article-title>. <source>Toxicol Sci</source><volume>148</volume>(<issue>1</issue>):<fpage>137</fpage>–<lpage>154</lpage>, PMID: 26272952, <pub-id pub-id-type="doi">10.1093/toxsci/kfv168</pub-id>.<?supplied-pmid 26272952?><pub-id pub-id-type="pmid">26272952</pub-id></mixed-citation>
    </ref>
    <ref id="c42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kavlock</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Austin</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Tice</surname><given-names>RR</given-names></name></person-group><year>2009</year>. <article-title>Toxicity testing in the 21st century: implications for human health risk assessment</article-title>. <source>Risk Anal</source><volume>29</volume>(<issue>4</issue>):<fpage>485</fpage>–<lpage>487</lpage>, PMID: 19076321, <pub-id pub-id-type="doi">10.1111/j.1539-6924.2008.01168.x</pub-id>.<?supplied-pmid 19076321?><pub-id pub-id-type="pmid">19076321</pub-id></mixed-citation>
    </ref>
    <ref id="c43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keiser</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Armbruster</surname><given-names>BN</given-names></name>, <name name-style="western"><surname>Ernsberger</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Irwin</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Shoichet</surname><given-names>BK</given-names></name></person-group><year>2007</year>. <article-title>Relating protein pharmacology by ligand chemistry</article-title>. <source>Nat Biotechnol</source><volume>25</volume>(<issue>2</issue>):<fpage>197</fpage>–<lpage>206</lpage>, PMID: 17287757, <pub-id pub-id-type="doi">10.1038/nbt1284</pub-id>.<?supplied-pmid 17287757?><pub-id pub-id-type="pmid">17287757</pub-id></mixed-citation>
    </ref>
    <ref id="c44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitamura</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jinno</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ohta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kuroki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fujimoto</surname><given-names>N</given-names></name></person-group><year>2002</year>. <article-title>Thyroid hormonal activity of the flame retardants tetrabromobisphenol A and tetrachlorobisphenol A</article-title>. <source>Biochem Biophys Res Commun</source><volume>293</volume>(<issue>1</issue>):<fpage>554</fpage>–<lpage>559</lpage>, PMID: 12054637, <pub-id pub-id-type="doi">10.1016/S0006-291X(02)00262-0</pub-id>.<?supplied-pmid 12054637?><pub-id pub-id-type="pmid">12054637</pub-id></mixed-citation>
    </ref>
    <ref id="c45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinstreuer</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Ceger</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Watt</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Houck</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Browne</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group><year>2017</year>. <article-title>Development and validation of a computational model for androgen receptor activity</article-title>. <source>Chem Res Toxicol</source>, PMID: 27933809, <pub-id pub-id-type="doi">10.1021/acs.chemrestox.6b00347</pub-id>.<?supplied-pmid 27933809?><pub-id pub-id-type="pmid">27933809</pub-id></mixed-citation>
    </ref>
    <ref id="c46">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koizumi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yamada</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Inada</surname><given-names>M</given-names></name></person-group><year>1984</year>. <article-title>Effect of mefenamic acid on plasma protein-thyroid hormone interaction, monodeiodination of thyroxine, urinary excretion of tri-iodothyronine and thyrotropin regulation</article-title>. <source>Clin Exp Pharmacol Physiol</source><volume>11</volume>(<issue>3</issue>):<fpage>291</fpage>–<lpage>299</lpage>, PMID: 6744687, <pub-id pub-id-type="doi">10.1111/j.1440-1681.1984.tb00267.x</pub-id>.<?supplied-pmid 6744687?><pub-id pub-id-type="pmid">6744687</pub-id></mixed-citation>
    </ref>
    <ref id="c47">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kojima</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Takeuchi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Uramaru</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sugihara</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kitamura</surname><given-names>S</given-names></name></person-group><year>2009</year>. <article-title>Nuclear hormone receptor activity of polybrominated diphenyl ethers and their hydroxylated and methoxylated metabolites in transactivation assays using Chinese hamster ovary cells</article-title>. <source>Environ Health Perspect</source><volume>117</volume>(<issue>8</issue>):<fpage>1210</fpage>–<lpage>1218</lpage>, PMID: 19672399, <pub-id pub-id-type="doi">10.1289/ehp.0900753</pub-id>.<?supplied-pmid 19672399?><pub-id pub-id-type="pmid">19672399</pub-id></mixed-citation>
    </ref>
    <ref id="c48">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kollitz</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>De Carbonnel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Stapleton</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Lee Ferguson</surname><given-names>P</given-names></name></person-group><year>2018</year>. <article-title>The affinity of brominated phenolic compounds for human and zebrafish thyroid receptor β: influence of chemical structure</article-title>. <source>Toxicol Sci</source><volume>163</volume>(<issue>1</issue>):<fpage>226</fpage>–<lpage>239</lpage>, PMID: 29409039, <pub-id pub-id-type="doi">10.1093/toxsci/kfy028</pub-id>.<?supplied-pmid 29409039?><pub-id pub-id-type="pmid">29409039</pub-id></mixed-citation>
    </ref>
    <ref id="c49">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kooistra</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Crawford</surname><given-names>S</given-names></name>, <name name-style="western"><surname>van Baar</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Brouwers</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Pop</surname><given-names>VJ</given-names></name></person-group><year>2006</year>. <article-title>Neonatal effects of maternal hypothyroxinemia during early pregnancy</article-title>. <source>Pediatrics</source><volume>117</volume>(<issue>1</issue>):<fpage>161</fpage>–<lpage>167</lpage>, PMID: 16396874, <pub-id pub-id-type="doi">10.1542/peds.2005-0227</pub-id>.<?supplied-pmid 16396874?><pub-id pub-id-type="pmid">16396874</pub-id></mixed-citation>
    </ref>
    <ref id="c50">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhn</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Voorhees</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Strader</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Shenk</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>CM</given-names></name>, <etal>et al.</etal></person-group><year>2007</year>. <article-title>Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma</article-title>. <source>Blood</source><volume>110</volume>(<issue>9</issue>):<fpage>3281</fpage>–<lpage>3290</lpage>, PMID: 17591945, <pub-id pub-id-type="doi">10.1182/blood-2007-01-065888</pub-id>.<?supplied-pmid 17591945?><pub-id pub-id-type="pmid">17591945</pub-id></mixed-citation>
    </ref>
    <ref id="c51">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauder</surname><given-names>JM</given-names></name></person-group><year>1977</year>. <article-title>The effects of early hypo- and hyperthyroidism on the development of rat cerebellar cortex. III. Kinetics of cell proliferation in the external granular layer</article-title>. <source>Brain Res</source><volume>126</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>51</lpage>, PMID: 856416, <pub-id pub-id-type="doi">10.1016/0006-8993(77)90213-X</pub-id>.<?supplied-pmid 856416?><pub-id pub-id-type="pmid">856416</pub-id></mixed-citation>
    </ref>
    <ref id="c52">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yen</surname><given-names>PM</given-names></name></person-group><year>1999</year>. <article-title>Recent advances in understanding thyroid hormone receptor coregulators</article-title>. <source>J Biomed Sci</source><volume>6</volume>(<issue>2</issue>):<fpage>71</fpage>–<lpage>78</lpage>, PMID: 10087437, <pub-id pub-id-type="doi">10.1007/BF02256437</pub-id>.<?supplied-pmid 10087437?><pub-id pub-id-type="pmid">10087437</pub-id></mixed-citation>
    </ref>
    <ref id="c53">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group><year>2010</year>. <article-title>Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25–30 months</article-title>. <source>Clin Endocrinol (Oxf)</source><volume>72</volume>(<issue>6</issue>):<fpage>825</fpage>–<lpage>829</lpage>, PMID: 19878506, <pub-id pub-id-type="doi">10.1111/j.1365-2265.2009.03743.x</pub-id>.<?supplied-pmid 19878506?><pub-id pub-id-type="pmid">19878506</pub-id></mixed-citation>
    </ref>
    <ref id="c54">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Scanlan</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Furlow</surname><given-names>JD</given-names></name></person-group><year>2002</year>. <article-title>A thyroid hormone antagonist that inhibits thyroid hormone action <italic>in vivo</italic></article-title>. <source>J Biol Chem</source><volume>277</volume>(<issue>38</issue>):<fpage>35664</fpage>–<lpage>35670</lpage>, PMID: 12095994, <pub-id pub-id-type="doi">10.1074/jbc.M205608200</pub-id>.<?supplied-pmid 12095994?><pub-id pub-id-type="pmid">12095994</pub-id></mixed-citation>
    </ref>
    <ref id="c55">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonard</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Lanz</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>O’Malley</surname><given-names>BW</given-names></name></person-group><year>2007</year>. <article-title>Nuclear receptor coregulators and human disease</article-title>. <source>Endocr Rev</source><volume>28</volume>(<issue>5</issue>):<fpage>575</fpage>–<lpage>587</lpage>, PMID: 17609497, <pub-id pub-id-type="doi">10.1210/er.2007-0012</pub-id>.<?supplied-pmid 17609497?><pub-id pub-id-type="pmid">17609497</pub-id></mixed-citation>
    </ref>
    <ref id="c56">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martínez</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Nascimento</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Nunes</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Aparicio</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dias</surname><given-names>SMG</given-names></name>, <etal>et al.</etal></person-group><year>2009</year>. <article-title>Gaining ligand selectivity in thyroid hormone receptors via entropy</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>106</volume>(<issue>49</issue>):<fpage>20717</fpage>–<lpage>20722</lpage>, PMID: 19926848, <pub-id pub-id-type="doi">10.1073/pnas.0911024106</pub-id>.<?supplied-pmid 19926848?><pub-id pub-id-type="pmid">19926848</pub-id></mixed-citation>
    </ref>
    <ref id="c57">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKinnon</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Richard</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mortimer</surname><given-names>R</given-names></name></person-group><year>2005</year>. <article-title>Synthesis of thyroid hormone binding proteins transthyretin and albumin by human trophoblast</article-title>. <source>J Clin Endocrinol Metab</source><volume>90</volume>(<issue>12</issue>):<fpage>6714</fpage>–<lpage>6720</lpage>, PMID: 16159939, <pub-id pub-id-type="doi">10.1210/jc.2005-0696</pub-id>.<?supplied-pmid 16159939?><pub-id pub-id-type="pmid">16159939</pub-id></mixed-citation>
    </ref>
    <ref id="c58">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meerts</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Letcher</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Hoving</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Marsh</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bergman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lemmen</surname><given-names>JG</given-names></name>, <etal>et al.</etal></person-group><year>2001</year>. <article-title>In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds</article-title>. <source>Environ Health Perspect</source><volume>109</volume>(<issue>4</issue>):<fpage>399</fpage>–<lpage>407</lpage>, PMID: 11335189, <pub-id pub-id-type="doi">10.1289/ehp.01109399</pub-id>.<?supplied-pmid 11335189?><pub-id pub-id-type="pmid">11335189</pub-id></mixed-citation>
    </ref>
    <ref id="c59">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meerts</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>van Zanden</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Luijks</surname><given-names>EAC</given-names></name>, <name name-style="western"><surname>van Leeuwen-Bol</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Marsh</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Jakobsson</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group><year>2000</year>. <article-title>Potent competitive interactions of some brominated flame retardants and related compounds with human transthyretin <italic>in vitro</italic></article-title>. <source>Toxicol Sci</source><volume>56</volume>(<issue>1</issue>):<fpage>95</fpage>–<lpage>104</lpage>, PMID: 10869457, <pub-id pub-id-type="doi">10.1093/toxsci/56.1.95</pub-id>.<?supplied-pmid 10869457?><pub-id pub-id-type="pmid">10869457</pub-id></mixed-citation>
    </ref>
    <ref id="c60">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Crofton</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Zoeller</surname><given-names>RT</given-names></name></person-group><year>2009</year>. <article-title>Thyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes</article-title>. <source>Environ Health Perspect</source><volume>117</volume>(<issue>7</issue>):<fpage>1033</fpage>–<lpage>1041</lpage>, PMID: 19654909, <pub-id pub-id-type="doi">10.1289/ehp.0800247</pub-id>.<?supplied-pmid 19654909?><pub-id pub-id-type="pmid">19654909</pub-id></mixed-citation>
    </ref>
    <ref id="c61">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyazaki</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Iwasaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Takeshita</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tohyama</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Koibuchi</surname><given-names>N</given-names></name></person-group><year>2008</year>. <article-title>Identification of the functional domain of thyroid hormone receptor responsible for polychlorinated biphenyl-mediated suppression of its action <italic>in vitro</italic></article-title>. <source>Environ Health Perspect</source><volume>116</volume>(<issue>9</issue>):<fpage>1231</fpage>–<lpage>1236</lpage>, PMID: 18795168, <pub-id pub-id-type="doi">10.1289/ehp.11176</pub-id>.<?supplied-pmid 18795168?><pub-id pub-id-type="pmid">18795168</pub-id></mixed-citation>
    </ref>
    <ref id="c62">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moriyama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tagami</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Akamizu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Usui</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Saijo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kanamoto</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group><year>2002</year>. <article-title>Thyroid hormone action is disrupted by bisphenol A as an antagonist</article-title>. <source>J Clin Endocrinol Metab</source><volume>87</volume>(<issue>11</issue>):<fpage>5185</fpage>–<lpage>5190</lpage>, PMID: 12414890, <pub-id pub-id-type="doi">10.1210/jc.2002-020209</pub-id>.<?supplied-pmid 12414890?><pub-id pub-id-type="pmid">12414890</pub-id></mixed-citation>
    </ref>
    <ref id="c63">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morreale de Escobar</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Obregón</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Escobar del Rey</surname><given-names>F</given-names></name></person-group><year>2000</year>. <article-title>Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia?</article-title><source>J Clin Endocrinol Metab</source><volume>85</volume>(<issue>11</issue>):<fpage>3975</fpage>–<lpage>3987</lpage>, PMID: 11095417, <pub-id pub-id-type="doi">10.1210/jcem.85.11.6961</pub-id>.<?supplied-pmid 11095417?><pub-id pub-id-type="pmid">11095417</pub-id></mixed-citation>
    </ref>
    <ref id="c64">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munro</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Barlow</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Craik</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Topliss</surname><given-names>DJ</given-names></name>, <etal>et al.</etal></person-group><year>1989</year>. <article-title>Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin</article-title>. <source>J Clin Endocrinol Metab</source><volume>68</volume>(<issue>6</issue>):<fpage>1141</fpage>–<lpage>1147</lpage>, PMID: 2498384, <pub-id pub-id-type="doi">10.1210/jcem-68-6-1141</pub-id>.<?supplied-pmid 2498384?><pub-id pub-id-type="pmid">2498384</pub-id></mixed-citation>
    </ref>
    <ref id="c65">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murk</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Rijntjes</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Blaauboer</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Clewell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Crofton</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Dingemans</surname><given-names>MM</given-names></name>, <etal>et al.</etal></person-group><year>2013</year>. <article-title>Mechanism-based testing strategy using <italic>in vitro</italic> approaches for identification of thyroid hormone disrupting chemicals</article-title>. <source>Toxicol In Vitro</source><volume>27</volume>(<issue>4</issue>):<fpage>1320</fpage>–<lpage>1346</lpage>, PMID: 23453986, <pub-id pub-id-type="doi">10.1016/j.tiv.2013.02.012</pub-id>.<?supplied-pmid 23453986?><pub-id pub-id-type="pmid">23453986</pub-id></mixed-citation>
    </ref>
    <ref id="c66">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norman</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Lavin</surname><given-names>TN</given-names></name></person-group><year>1989</year>. <article-title>Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells</article-title>. <source>J Clin Invest</source><volume>83</volume>(<issue>1</issue>):<fpage>306</fpage>–<lpage>313</lpage>, PMID: 2910914, <pub-id pub-id-type="doi">10.1172/JCI113874</pub-id>.<?supplied-pmid 2910914?><pub-id pub-id-type="pmid">2910914</pub-id></mixed-citation>
    </ref>
    <ref id="c67">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O’Shaughnessy</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Kosian</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Ford</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Oshiro</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Degitz</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Gilbert</surname><given-names>ME</given-names></name></person-group><year>2018</year>. <article-title>Developmental thyroid hormone insufficiency induces a cortical brain malformation and learning impairments: a cross-fostering study</article-title>. <source>Toxicol Sci</source><volume>163</volume>(<issue>1</issue>):<fpage>101</fpage>–<lpage>115</lpage>, PMID: 29385626, <pub-id pub-id-type="doi">10.1093/toxsci/kfy016</pub-id>.<?supplied-pmid 29385626?><pub-id pub-id-type="pmid">29385626</pub-id></mixed-citation>
    </ref>
    <ref id="c68">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oetting</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yen</surname><given-names>PM</given-names></name></person-group><year>2007</year>. <article-title>New insights into thyroid hormone action</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source><volume>21</volume>(<issue>2</issue>):<fpage>193</fpage>–<lpage>208</lpage>, PMID: 17574003, <pub-id pub-id-type="doi">10.1016/j.beem.2007.04.004</pub-id>.<?supplied-pmid 17574003?><pub-id pub-id-type="pmid">17574003</pub-id></mixed-citation>
    </ref>
    <ref id="c69">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul Friedman</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Watt</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Hornung</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Hedge</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Judson</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Crofton</surname><given-names>KM</given-names></name>, <etal>et al.</etal></person-group><year>2016</year>. <article-title>Tiered high-throughput screening approach to identify thyroperoxidase inhibitors within the ToxCast phase I and II chemical libraries</article-title>. <source>Toxicol Sci</source><volume>151</volume>(<issue>1</issue>):<fpage>160</fpage>–<lpage>180</lpage>, PMID: 26884060, <pub-id pub-id-type="doi">10.1093/toxsci/kfw034</pub-id>.<?supplied-pmid 26884060?><pub-id pub-id-type="pmid">26884060</pub-id></mixed-citation>
    </ref>
    <ref id="c70">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulus</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Whitehouse</surname><given-names>MW</given-names></name></person-group><year>1973</year>. <article-title>Nonsteroid anti-inflammatory agents</article-title>. <source>Annu Rev Pharmacol</source><volume>13</volume>:<fpage>107</fpage>–<lpage>125</lpage>, PMID: 4576885, <pub-id pub-id-type="doi">10.1146/annurev.pa.13.040173.000543</pub-id>.<?supplied-pmid 4576885?><pub-id pub-id-type="pmid">4576885</pub-id></mixed-citation>
    </ref>
    <ref id="c71">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pop</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Brouwers</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Vader</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Vulsma</surname><given-names>T</given-names></name>, <name name-style="western"><surname>van Baar</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>de Vijlder</surname><given-names>JJ</given-names></name></person-group><year>2003</year>. <article-title>Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study</article-title>. <source>Clin Endocrinol (Oxf)</source><volume>59</volume>(<issue>3</issue>):<fpage>282</fpage>–<lpage>288</lpage>, PMID: 12919150, <pub-id pub-id-type="doi">10.1046/j.1365-2265.2003.01822.x</pub-id>.<?supplied-pmid 12919150?><pub-id pub-id-type="pmid">12919150</pub-id></mixed-citation>
    </ref>
    <ref id="c72">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pop</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Kuijpens</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>van Baar</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Verkerk</surname><given-names>G</given-names></name>, <name name-style="western"><surname>van Son</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>de Vijlder</surname><given-names>JJ</given-names></name>, <etal>et al.</etal></person-group><year>1999</year>. <article-title>Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy</article-title>. <source>Clin Endocrinol (Oxf)</source><volume>50</volume>(<issue>2</issue>):<fpage>149</fpage>–<lpage>155</lpage>, PMID: 10396355, <pub-id pub-id-type="doi">10.1046/j.1365-2265.1999.00639.x</pub-id>.<?supplied-pmid 10396355?><pub-id pub-id-type="pmid">10396355</pub-id></mixed-citation>
    </ref>
    <ref id="c73">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porterfield</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Hendrich</surname><given-names>CE</given-names></name></person-group><year>1993</year>. <article-title>The role of thyroid hormones in prenatal and neonatal neurological development—current perspectives</article-title>. <source>Endocr Rev</source><volume>14</volume>:<fpage>94</fpage>–<lpage>106</lpage>, PMID: 8491157, <pub-id pub-id-type="doi">10.1210/edrv-14-1-94</pub-id>.<?supplied-pmid 8491157?><pub-id pub-id-type="pmid">8491157</pub-id></mixed-citation>
    </ref>
    <ref id="c74">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quignodon</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Legrand</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Allioli</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Guadaño-Ferraz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bernal</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Samarut</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group><year>2004</year>. <article-title>Thyroid hormone signaling is highly heterogeneous during pre- and postnatal brain development</article-title>. <source>J Mol Endocrinol</source><volume>33</volume>(<issue>2</issue>):<fpage>467</fpage>–<lpage>476</lpage>, PMID: 15525602, <pub-id pub-id-type="doi">10.1677/jme.1.01570</pub-id>.<?supplied-pmid 15525602?><pub-id pub-id-type="pmid">15525602</pub-id></mixed-citation>
    </ref>
    <ref id="c75">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Apriletti</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>West</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Huber</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group><year>1998</year>. <article-title>Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies</article-title>. <source>Recent Prog Horm Res</source><volume>53</volume>:<fpage>351</fpage>–<lpage>392</lpage>, PMID: 9769715.<?supplied-pmid 9769715?><pub-id pub-id-type="pmid">9769715</pub-id></mixed-citation>
    </ref>
    <ref id="c76">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Barone</surname><given-names>S</given-names><suffix>Jr.</suffix></name></person-group><year>2000</year>. <article-title>Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models</article-title>. <source>Environ Health Perspect</source><volume>108</volume>(<issue>Suppl 3</issue>):<fpage>511</fpage>–<lpage>533</lpage>, PMID: 10852851, <pub-id pub-id-type="doi">10.1289/ehp.00108s3511</pub-id>.<?supplied-pmid 10852851?><pub-id pub-id-type="pmid">10852851</pub-id></mixed-citation>
    </ref>
    <ref id="c77">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riss</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Moravec</surname><given-names>RA</given-names></name></person-group><year>2004</year>. <article-title>Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays</article-title>. <source>Assay Drug Dev Technol</source><volume>2</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>62</lpage>, PMID: 15090210, <pub-id pub-id-type="doi">10.1089/154065804322966315</pub-id>.<?supplied-pmid 15090210?><pub-id pub-id-type="pmid">15090210</pub-id></mixed-citation>
    </ref>
    <ref id="c78">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosman</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Malone</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Helfenstein</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kraft</surname><given-names>E</given-names></name></person-group><year>1972</year>. <article-title>The effect of thyroid deficiency on myelination of brain. A morphological and biochemical study</article-title>. <source>Neurology</source><volume>22</volume>(<issue>1</issue>):<fpage>99</fpage>–<lpage>106</lpage>, PMID: 5061842, <pub-id pub-id-type="doi">10.1212/wnl.22.1.99</pub-id>.<?supplied-pmid 5061842?><pub-id pub-id-type="pmid">5061842</pub-id></mixed-citation>
    </ref>
    <ref id="c79">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schapira</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Raaka</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Totrov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group><year>2003</year>. <article-title>Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>100</volume>(<issue>12</issue>):<fpage>7354</fpage>–<lpage>7359</lpage>, PMID: 12777627, <pub-id pub-id-type="doi">10.1073/pnas.1131854100</pub-id>.<?supplied-pmid 12777627?><pub-id pub-id-type="pmid">12777627</pub-id></mixed-citation>
    </ref>
    <ref id="c80">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schriks</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vrabie</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Gutleb</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Faassen</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Rietjens</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Murk</surname><given-names>AJ</given-names></name></person-group><year>2006</year>. <article-title>T-screen to quantify functional potentiating, antagonistic and thyroid hormone-like activities of poly halogenated aromatic hydrocarbons (PHAHs)</article-title>. <source>Toxicol In Vitro</source><volume>20</volume>(<issue>4</issue>):<fpage>490</fpage>–<lpage>498</lpage>, PMID: 16219445, <pub-id pub-id-type="doi">10.1016/j.tiv.2005.09.001</pub-id>.<?supplied-pmid 16219445?><pub-id pub-id-type="pmid">16219445</pub-id></mixed-citation>
    </ref>
    <ref id="c81">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanton</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Cahill</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Dotson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tomaselli</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Wasvary</surname><given-names>JM</given-names></name>, <etal>et al.</etal></person-group><year>2000</year>. <article-title>Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to <sc>l</sc>-thyronine</article-title>. <source>Bioorg Med Chem Lett</source><volume>10</volume>(<issue>15</issue>):<fpage>1661</fpage>–<lpage>1663</lpage>, PMID: 10937719, <pub-id pub-id-type="doi">10.1016/S0960-894X(00)00309-7</pub-id>.<?supplied-pmid 10937719?><pub-id pub-id-type="pmid">10937719</pub-id></mixed-citation>
    </ref>
    <ref id="c82">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stavreva</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Varticovski</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Levkova</surname><given-names>L</given-names></name>, <name name-style="western"><surname>George</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pegoraro</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group><year>2016</year>. <article-title>Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants</article-title>. <source>Toxicology</source><volume>368–369</volume>:<fpage>69</fpage>–<lpage>79</lpage>, PMID: 27528272, <pub-id pub-id-type="doi">10.1016/j.tox.2016.08.012</pub-id>.<?supplied-pmid 27528272?><pub-id pub-id-type="pmid">27528272</pub-id></mixed-citation>
    </ref>
    <ref id="c83">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tancevski</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Rudling</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Eller</surname><given-names>P</given-names></name></person-group><year>2011</year>. <article-title>Thyromimetics: a journey from bench to bed-side</article-title>. <source>Pharmacol Ther</source><volume>131</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>39</lpage>, PMID: 21504761, <pub-id pub-id-type="doi">10.1016/j.pharmthera.2011.04.003</pub-id>.<?supplied-pmid 21504761?><pub-id pub-id-type="pmid">21504761</pub-id></mixed-citation>
    </ref>
    <ref id="c84">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorne</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Auld</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Inglese</surname><given-names>J</given-names></name></person-group><year>2010</year>. <article-title>Apparent activity in high-throughput screening: origins of compound-dependent assay interference</article-title>. <source>Curr Opin Chem Biol</source><volume>14</volume>(<issue>3</issue>):<fpage>315</fpage>–<lpage>324</lpage>, PMID: 20417149, <pub-id pub-id-type="doi">10.1016/j.cbpa.2010.03.020</pub-id>.<?supplied-pmid 20417149?><pub-id pub-id-type="pmid">20417149</pub-id></mixed-citation>
    </ref>
    <ref id="c85">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valadares</surname><given-names>NF</given-names></name>, <name name-style="western"><surname>Salum</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Polikarpov</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Andricopulo</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Garratt</surname><given-names>RC</given-names></name></person-group><year>2009</year>. <article-title>Role of halogen bonds in thyroid hormone receptor selectivity: pharmacophore-based 3D-QSSR studies</article-title>. <source>J Chem Inf Model</source><volume>49</volume>(<issue>11</issue>):<fpage>2606</fpage>–<lpage>2616</lpage>, PMID: 19863110, <pub-id pub-id-type="doi">10.1021/ci900316e</pub-id>.<?supplied-pmid 19863110?><pub-id pub-id-type="pmid">19863110</pub-id></mixed-citation>
    </ref>
    <ref id="c86">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Apriletti</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>McGrath</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>West</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Baxter</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Fletterick</surname><given-names>RJ</given-names></name></person-group><year>1995</year>. <article-title>A structural role for hormone in the thyroid hormone receptor</article-title>. <source>Nature</source><volume>378</volume>(<issue>6558</issue>):<fpage>690</fpage>–<lpage>697</lpage>, PMID: 7501015, <pub-id pub-id-type="doi">10.1038/378690a0</pub-id>.<?supplied-pmid 7501015?><pub-id pub-id-type="pmid">7501015</pub-id></mixed-citation>
    </ref>
    <ref id="c87">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Dudazy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>van Hogerlinden</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nordström</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mittag</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vennström</surname><given-names>B</given-names></name></person-group><year>2010</year>. <article-title>The thyroid hormone receptor α1 protein is expressed in embryonic postmitotic neurons and persists in most adult neurons</article-title>. <source>Mol Endocrinol</source><volume>24</volume>(<issue>10</issue>):<fpage>1904</fpage>–<lpage>1916</lpage>, PMID: 20739404, <pub-id pub-id-type="doi">10.1210/me.2010-0175</pub-id>.<?supplied-pmid 20739404?><pub-id pub-id-type="pmid">20739404</pub-id></mixed-citation>
    </ref>
    <ref id="c88">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hallinger</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Murr</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Buckalew</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Simmons</surname><given-names>SO</given-names></name>, <name name-style="western"><surname>Laws</surname><given-names>SC</given-names></name>, <etal>et al.</etal></person-group><year>2018</year>. <article-title>High-throughput screening and quantitative chemical ranking for sodium-iodide symporter inhibitors in ToxCast phase I chemical library</article-title>. <source>Environ Sci Technol</source><volume>52</volume>(<issue>9</issue>):<fpage>5417</fpage>–<lpage>5426</lpage>, PMID: 29611697, <pub-id pub-id-type="doi">10.1021/acs.est.7b06145</pub-id>.<?supplied-pmid 29611697?><pub-id pub-id-type="pmid">29611697</pub-id></mixed-citation>
    </ref>
    <ref id="c89">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shim</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Dang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group><year>2014</year>. <article-title>Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer</article-title>. <source>Br J Pharmacol</source><volume>171</volume>(<issue>19</issue>):<fpage>4478</fpage>–<lpage>4489</lpage>, PMID: 24903412, <pub-id pub-id-type="doi">10.1111/bph.12800</pub-id>.<?supplied-pmid 24903412?><pub-id pub-id-type="pmid">24903412</pub-id></mixed-citation>
    </ref>
    <ref id="c90">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>R</given-names></name></person-group><year>2016</year>. <article-title>Correction of microplate data from high-throughput screening</article-title>. <source>Methods Mol Biol</source><volume>1473</volume>:<fpage>123</fpage>–<lpage>134</lpage>, PMID: 27518630, <pub-id pub-id-type="doi">10.1007/978-1-4939-6346-1_13</pub-id>.<?supplied-pmid 27518630?><pub-id pub-id-type="pmid">27518630</pub-id></mixed-citation>
    </ref>
    <ref id="c91">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webb</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>N-H</given-names></name>, <name name-style="western"><surname>Chiellini</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yoshihara</surname><given-names>HAI</given-names></name>, <name name-style="western"><surname>Cunha Lima</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Apriletti</surname><given-names>JW</given-names></name>, <etal>et al.</etal></person-group><year>2002</year>. <article-title>Design of thyroid hormone receptor antagonists from first principles</article-title>. <source>J Steroid Biochem Mol Biol</source><volume>83</volume>(<issue>1–5</issue>):<fpage>59</fpage>–<lpage>73</lpage>, PMID: 12650702, <pub-id pub-id-type="doi">10.1016/S0960-0760(02)00270-4</pub-id>.<?supplied-pmid 12650702?><pub-id pub-id-type="pmid">12650702</pub-id></mixed-citation>
    </ref>
    <ref id="c92">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetzler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Segal</surname><given-names>D</given-names></name></person-group><year>2011</year>. <article-title>Omacetaxine as an anticancer therapeutic: what is old is new again</article-title>. <source>Curr Pharm Des</source><volume>17</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>64</lpage>, PMID: 21294709, <pub-id pub-id-type="doi">10.2174/138161211795049778</pub-id>.<?supplied-pmid 21294709?><pub-id pub-id-type="pmid">21294709</pub-id></mixed-citation>
    </ref>
    <ref id="c93">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>GR</given-names></name></person-group><year>2008</year>. <article-title>Neurodevelopmental and neurophysiological actions of thyroid hormone</article-title>. <source>J Neuroendocrinol</source><volume>20</volume>(<issue>6</issue>):<fpage>784</fpage>–<lpage>794</lpage>, PMID: 18601701, <pub-id pub-id-type="doi">10.1111/j.1365-2826.2008.01733.x</pub-id>.<?supplied-pmid 18601701?><pub-id pub-id-type="pmid">18601701</pub-id></mixed-citation>
    </ref>
    <ref id="c94">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yen</surname><given-names>PM</given-names></name></person-group><year>2001</year>. <article-title>Physiological and molecular basis of thyroid hormone action</article-title>. <source>Physiol Rev</source><volume>81</volume>(<issue>3</issue>):<fpage>1097</fpage>–<lpage>1142</lpage>, PMID: 11427693, <pub-id pub-id-type="doi">10.1152/physrev.2001.81.3.1097</pub-id>.<?supplied-pmid 11427693?><pub-id pub-id-type="pmid">11427693</pub-id></mixed-citation>
    </ref>
    <ref id="c95">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>DeVito</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Crofton</surname><given-names>KM</given-names></name></person-group><year>2002</year>. <article-title>Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption</article-title>. <source>Toxicol Sci</source><volume>66</volume>(<issue>1</issue>):<fpage>105</fpage>–<lpage>116</lpage>, PMID: 11861977, <pub-id pub-id-type="doi">10.1093/toxsci/66.1.105</pub-id>.<?supplied-pmid 11861977?><pub-id pub-id-type="pmid">11861977</pub-id></mixed-citation>
    </ref>
    <ref id="c96">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoeller</surname><given-names>RT</given-names></name></person-group><year>2005</year>. <article-title>Environmental chemicals as thyroid hormone analogues: new studies indicate that thyroid hormone receptors are targets of industrial chemicals?</article-title><source>Mol Cell Endocrinol</source><volume>242</volume>(<issue>1–2</issue>):<fpage>10</fpage>–<lpage>15</lpage>, PMID: 16150534, <pub-id pub-id-type="doi">10.1016/j.mce.2005.07.006</pub-id>.<?supplied-pmid 16150534?><pub-id pub-id-type="pmid">16150534</pub-id></mixed-citation>
    </ref>
    <ref id="c97">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoeller</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Crofton</surname><given-names>KM</given-names></name></person-group><year>2000</year>. <article-title>Thyroid hormone action in fetal brain development and potential for disruption by environmental chemicals</article-title>. <source>Neurotoxicology</source><volume>21</volume>(<issue>6</issue>):<fpage>935</fpage>–<lpage>945</lpage>, PMID: 11233763.<?supplied-pmid 11233763?><pub-id pub-id-type="pmid">11233763</pub-id></mixed-citation>
    </ref>
    <ref id="c98">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoeller</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Tyl</surname><given-names>RW</given-names></name></person-group><year>2007</year>. <article-title>General background on the hypothalamic-pituitary-thyroid (HPT) axis</article-title>. <source>Crit Rev Toxicol</source><volume>37</volume>(<issue>1–2</issue>):<fpage>11</fpage>–<lpage>53</lpage>, PMID: 17364704, <pub-id pub-id-type="doi">10.1080/10408440601123446</pub-id>.<?supplied-pmid 17364704?><pub-id pub-id-type="pmid">17364704</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
